GSK plc 6-K, filed Apr 26, 2023
GSK plc (GSK)
6-K
2023-04-26
For: 2023-04-26
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on April 26, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of April 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
|
Q1 2023 performance highlights:
|
|
|
●
|
Sales
performance reflected lower COVID-19 solutions sales versus Q1
2022. Excluding COVID-19 solutions, sales grew +10% CER with strong
performance across Vaccines, Specialty and General
Medicines
|
|
●
|
Key
growth drivers included Shingrix for shingles, meningitis
vaccines, oral two-drug regimen and long-acting HIV medicines,
Benlysta in immunology,
Nucala and Trelegy in respiratory, which combined
contributed more than 40% of sales
|
|
●
|
Total
operating profit and total EPS performance reflected the comparison
to Q1 2022 which included the one-off income benefit of the Gilead
settlement and higher Xevudy sales
|
|
●
|
Adjusted
operating profit was stable at CER, predominately reflecting a 5%
adverse impact following expected lower COVID-19 solutions sales
and 4% from legal provisions primarily relating to
royalties
|
|
●
|
Adjusted
EPS increased +7% CER due to lower non-controlling interests, a
lower effective tax rate, and strong sales growth excluding lower
COVID-19 solutions (which impacted performance by 7%)
|
|
●
|
Cash
generated from operations £0.3 billion; free cash outflow
(£0.7) billion lower than Q1 2022 primarily due to Gilead
settlement income received in Q1 2022 and timing of profit share
payments
|
|
●
|
Full-year
2023 guidance affirmed. Dividend of 14p declared for Q1 2023. 56.5p
expected for the full-year 2023
|
|
|
Q1 2023
|
||||
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
|
|
|
|
|
|
|
Vaccines
|
2,041
|
|
22
|
|
15
|
|
Specialty
Medicines
|
2,236
|
|
(29)
|
|
(33)
|
|
General
Medicines
|
2,674
|
|
12
|
|
9
|
|
|
|
|
|
|
|
|
Turnover
|
6,951
|
|
(3)
|
|
(8)
|
|
|
|
|
|
|
|
|
Turnover excluding COVID-19 solutions
|
6,819
|
|
16
|
|
10
|
|
|
|
|
|
|
|
|
Total operating profit
|
2,082
|
|
(9)
|
|
(15)
|
|
|
|
|
|
|
|
|
Total continuing EPS
|
36.8p
|
|
(1)
|
|
(8)
|
|
|
|
|
|
|
|
|
Total EPS
|
36.8p
|
|
(18)
|
|
(23)
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
2,092
|
|
8
|
|
-
|
|
|
|
|
|
|
|
|
Adjusted
operating margin %
|
30.1%
|
|
3.1
ppts
|
|
2.5
ppts
|
|
|
|
|
|
|
|
|
Adjusted
EPS
|
37.0p
|
|
15
|
|
7
|
|
|
|
|
|
|
|
|
Cash generated from operations
|
287
|
|
(88)
|
|
|
|
Free
cash outflow
|
(689)
|
|
>(100)
|
|
|
|
(Financial Performance - Q1 2023 results unless otherwise stated,
growth % and commentary at CER)
|
|
R&D delivery and targeted business development support future
growth
|
|
|
●
|
Innovative
pipeline of 68 vaccines and
specialty medicines based on the science of immune system with
17 in Phase III/registration;
four anticipated 2023 approvals (daprodustat in anaemia due to
chronic kidney disease, RSV older adults vaccine, momelotinib in
myelofibrosis and Jemperli
in first-line endometrial cancer)
|
|
●
|
Four
positive phase III/IV data readouts in Q1 2023, including
pentavalent Meningitis ABCWY vaccine candidate; gepotidacin for
uncomplicated urinary tract infections; Jemperli for first-line endometrial
cancer and Cabenuva for HIV treatment
|
|
●
|
Proposed
acquisition of Bellus Health – provides access to
camlipixant, potential best-in-class and highly selective P2X3
antagonist currently in phase III development for treatment of
refractory chronic cough; exclusive license agreement signed with
Scynexis for Brexafemme, a
US FDA approved, first-in-class antifungal for treatment of
vulvovaginal candidiasis
|
|
Emma Walmsley, Chief Executive Officer, GSK:
“We
have made a strong start to 2023, with excellent performance across
Vaccines, Specialty and General Medicines. We are very focused on
our upcoming launches, including our potential RSV older adult
vaccine, and on continuing to strengthen our pipeline – both
organically with several positive late-stage read-outs already this
year, and through targeted business development. This continued
momentum is also supporting our confidence in delivering our medium
and long-term growth ambitions.”
|
|
The Total results are presented in summary above and on page 6 and
Adjusted results reconciliations are presented on pages 18 and 19.
Adjusted results are a non-IFRS measure excluding discontinued
operations and other adjustments that may be considered in addition
to, but not as a substitute for, or superior to, information
presented in accordance with IFRS. Adjusted results are defined on
page 16 and £% or AER% growth, CER% growth, free cash flow,
turnover excluding COVID-19 solutions and other non-IFRS measures
are defined on page 44, COVID-19 solutions are defined on page 44.
GSK provides guidance on an Adjusted results basis only, for the
reasons set out on page 16. All expectations, guidance and targets
regarding future performance and dividend payments should be read
together with ‘Guidance, assumptions and cautionary
statements’ on pages 45 and 46.
|
|
The Q1 2022 comparative results are restated from
those previously published to reflect the demerger of Consumer
Healthcare in July 2022 see page 33.
|
|
2023 guidance
|
|
The
Company affirms its full-year 2023 guidance at constant exchange
rates (CER). All expectations and full-year growth rates exclude
any contributions from COVID-19 solutions:
|
|
Turnover is expected to increase between 6 to 8 per
cent
Adjusted operating profit is expected to
increase between 10 to 12 per
cent
Adjusted earnings per share is expected
to increase between 12 to 15 per
cent
|
|
Taking
Q1 2023 performance and the latest expectations for Q2 2023 into
account, GSK now expects first half and second half turnover growth
to be broadly similar and for General Medicines to be broadly flat
to slightly down this year. GSK expects Adjusted operating profit
growth to be lower in the first half of 2023 and higher in the
second half, relative to full-year expectations.
Despite
the recovery of healthcare systems, uncertain economic conditions
prevail across many markets in which GSK operates and we continue
to expect to see variability in performance between
quarters.
This
guidance is supported by the following turnover expectations for
full year 2023 at CER:
|
|
Vaccines – expected increase of mid-teens per cent in
turnover
Specialty Medicines – expected
increase of mid to high
single-digit per cent in turnover
General Medicines – expected to be
broadly flat to slightly
down
|
|
Adjusted
Operating profit is expected to grow between 10 to 12 per cent at
CER reflecting Cost of sales and R&D increasing at a rate
slightly below turnover, while SG&A is anticipated to increase
at a rate broadly aligned to turnover, reflecting targeted support
for launches and potential launches including the RSV older adult
candidate vaccine. Adjusted earnings per share is expected to
increase between 12 to 15 per cent at CER reflecting favourable net
finance costs and non-controlling interests plus an expected lower
tax rate, at around 15%.
|
|
Additional commentary
|
|
Dividend
policies and expected pay-out ratios remain unchanged for GSK. The
future dividend policies and guidance regarding the expected
dividend pay-out in 2023 for GSK are provided on page
30.
|
|
COVID-19 solutions
|
|
In Q1
2023, turnover decreased by 8% at CER reflecting the comparison to
Q1 2022, which included £1,307 million of COVID-19 solutions
sales in the period. Excluding COVID-19 solutions, turnover
increased by 10% at CER. In Q1 2023, Adjusted Operating profit was
stable at CER reflecting a 5% adverse impact from expected lower
COVID-19 solutions sales. Based on known binding agreements with
governments, GSK does not anticipate further significant COVID-19
pandemic-related sales or operating profit in 2023. Consequently,
the Company now expects full-year 2023 turnover growth to be
impacted by approximately 9%, with Adjusted Operating profit growth
being reduced between 5% to 6% versus the prior year.
All
expectations, guidance and targets regarding future performance and
dividend payments should be read together with ‘Guidance,
assumptions and cautionary statements’ on pages 45 and 46. If
exchange rates were to hold at the closing rates on 31 March 2023
($1.24/£1, €1.14/£1 and Yen 165/£1) for the
rest of 2023, the estimated impact on 2023 Sterling turnover growth
for GSK would be stable and if exchange gains or losses were
recognised at the same level as in 2022, the estimated impact on
2023 Sterling Adjusted Operating Profit growth for GSK would be
-1%.
|
|
Results presentation
|
|
A
conference call and webcast for investors and analysts of the
quarterly results will be hosted by Emma Walmsley, CEO, at 12pm GMT
on 26 April 2023. Presentation materials will be published on
www.gsk.com prior to the webcast and a transcript of the webcast
will be published subsequently.
Notwithstanding
the inclusion of weblinks, information available on the
Company’s website, or from non GSK sources, is not
incorporated by reference into this Results
Announcement.
|
|
Performance:
turnover
|
|
Turnover
|
|
Q1 2023
|
|||||||||
|
|
|
|
|
|
|
|
|||||
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shingles
|
|
833
|
|
19
|
|
11
|
|||||
|
Meningitis
|
|
280
|
|
32
|
|
25
|
|||||
|
Influenza
|
|
12
|
|
(33)
|
|
(28)
|
|||||
|
Established
Vaccines
|
|
815
|
|
10
|
|
4
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines
excluding COVID-19 solutions
|
|
1,940
|
|
16
|
|
9
|
|||||
|
COVID-19
solutions: Pandemic vaccines
|
|
101
|
|
100
|
|
100
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines
|
|
2,041
|
|
22
|
|
15
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
|
1,468
|
|
24
|
|
15
|
|||||
|
Immunology/Respiratory
and Other
|
|
601
|
|
16
|
|
9
|
|||||
|
Oncology
|
|
136
|
|
7
|
|
2
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Specialty
Medicines excluding COVID-19 solutions
|
|
2,205
|
|
21
|
|
13
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COVID-19
solutions: Xevudy
|
|
31
|
|
(98)
|
|
(98)
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Specialty Medicines
|
|
2,236
|
|
(29)
|
|
(33)
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
|
1,767
|
|
15
|
|
10
|
|||||
|
Other
General Medicines
|
|
907
|
|
7
|
|
7
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General Medicines
|
|
2,674
|
|
12
|
|
9
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
6,951
|
|
(3)
|
|
(8)
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total excluding COVID-19 solutions
|
|
6,819
|
|
16
|
|
10
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By Region:
|
|
|
|
|
|
|
|||||
|
US
|
|
3,270
|
|
(9)
|
|
(17)
|
|||||
|
Europe
|
|
1,704
|
|
3
|
|
(2)
|
|||||
|
International
|
|
1,977
|
|
2
|
|
2
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
6,951
|
|
(3)
|
|
(8)
|
|||||
|
|
|
|
|
|
|
||||||
|
Turnover excluding COVID-19 solutions is a
non-IFRS measure defined on page 44 with the reconciliation to the
IFRS measure Turnover included in the table
above.
|
|
Financial
performance
|
|
Total Results
|
Q1 2023
|
||||
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
|
|
|
|
|
|
|
Turnover
|
6,951
|
|
(3)
|
|
(8)
|
|
Cost of
sales
|
(1,943)
|
|
(28)
|
|
(30)
|
|
Selling,
general and administration
|
(2,143)
|
|
18
|
|
12
|
|
Research
and development
|
(1,260)
|
|
14
|
|
8
|
|
Royalty
income
|
180
|
|
30
|
|
28
|
|
Other
operating income/(expense)
|
297
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
2,082
|
|
(9)
|
|
(15)
|
|
|
|
|
|
|
|
|
Net
Finance expense
|
(174)
|
|
|
|
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(2)
|
|
|
|
|
|
Profit/(loss)
on disposal of interest in associates
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
1,907
|
|
(9)
|
|
(15)
|
|
|
|
|
|
|
|
|
Taxation
|
(276)
|
|
|
|
|
|
Tax rate %
|
14.5%
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
1,631
|
|
(8)
|
|
(14)
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
141
|
|
|
|
|
|
Profit
attributable to shareholders
|
1,490
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,631
|
|
(8)
|
|
(14)
|
|
|
|
|
|
|
|
|
Earnings
per share
|
36.8p
|
|
(1)
|
|
(8)
|
|
|
|
|
|
|
|
|
The Total Results are on a continuing basis. The Q1 2022
comparative results have been restated on a consistent basis from
those previously published to reflect the demerger of the Consumer
Healthcare business (see page 33). Financial Performance - Q1 2023
results unless otherwise stated, growth % and commentary at
CER.
|
|
Adjusted results
Reconciliations
between Total results and Adjusted results for Q1 2023 and Q1 2022
are set out on pages 18 and 19.
|
|
|
Q1 2023
|
||||
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
|
|
|
|
|
|
|
Turnover
|
6,951
|
|
(3)
|
|
(8)
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(1,752)
|
|
(31)
|
|
(32)
|
|
Selling,
general and administration
|
(2,065)
|
|
17
|
|
10
|
|
Research
and development
|
(1,222)
|
|
12
|
|
6
|
|
Royalty
income
|
180
|
|
30
|
|
28
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
2,092
|
|
8
|
|
-
|
|
|
|
|
|
|
|
|
Adjusted
profit before taxation
|
1,920
|
|
10
|
|
2
|
|
Taxation
|
(303)
|
|
6
|
|
(2)
|
|
|
|
|
|
|
|
|
Adjusted
profit after taxation
|
1,617
|
|
11
|
|
3
|
|
|
|
|
|
|
|
|
Adjusted
profit attributable to non-controlling interests
|
121
|
|
|
|
|
|
Adjusted
profit attributable to shareholders
|
1,496
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,617
|
|
11
|
|
3
|
|
|
|
|
|
|
|
|
Earnings
per share
|
37.0p
|
|
15
|
|
7
|
|
|
|
|
|
|
|
|
|
|
|
|
Q1 2023
|
||||
|
|
|
|
|
|
|
£m
|
AER
|
CER
|
|
Cost of
sales
|
Total
|
|
|
|
|
1,943
|
(28%)
|
(30%)
|
|
% of sales
|
|
|
|
|
28.0%
|
(9.8%)
|
(8.9%)
|
|
|
Adjusted
|
|
|
|
|
1,752
|
(31%)
|
(32%)
|
|
|
|
% of sales
|
|
|
|
|
25.2%
|
(9.9%)
|
(9.1%)
|
|
|
||||||||
|
The decrease in Total and Adjusted cost of sales as a percentage of
sales primarily reflected lower sales of lower margin
Xevudy
compared to Q1 2022. This was partly
offset by an unfavourable comparator to a one-time benefit from
inventory adjustments in Q1 2022 as well as higher freight
costs.
|
||||||||
|
|
|
|
|
Q1 2023
|
||||
|
|
|
|
|
|
|
£m
|
AER
|
CER
|
|
Selling,
general & administration
|
Total
|
|
|
|
|
2,143
|
18%
|
12%
|
|
% of sales
|
|
|
|
|
30.8%
|
5.6%
|
5.5%
|
|
|
Adjusted
|
|
|
|
|
2,065
|
17%
|
10%
|
|
|
|
% of sales
|
|
|
|
|
29.7%
|
5.1%
|
4.9%
|
|
|
||||||||
|
Growth
in Total and Adjusted SG&A primarily reflected an increase in
legal provisions primarily relating to the Zejula royalty
dispute(1) resulting
in an increase of 4 ppts and an increased level of launch
investment in Specialty Medicines particularly HIV and Vaccines
including Shingrix to drive
post-pandemic recovery demand and support market expansion. Growth
was partly offset by favourable comparison due to impairment
provisions relating to Russia and Ukraine in Q1 2022 and the
continuing benefit of restructuring and tight control of ongoing
costs.
|
||||||||
|
|
|
|
|
Q1 2023
|
||||
|
|
|
|
|
|
|
£m
|
AER
|
CER
|
|
Research
& development
|
Total
|
|
|
|
|
1,260
|
14%
|
8%
|
|
% of sales
|
|
|
|
|
18.1%
|
2.8%
|
2.7%
|
|
|
Adjusted
|
|
|
|
|
1,222
|
12%
|
6%
|
|
|
|
% of sales
|
|
|
|
|
17.6%
|
2.4%
|
2.4%
|
|
|
||||||||
|
Growth
in Total and Adjusted R&D reflected increased investment across
the Vaccines clinical development portfolio, particularly in
pneumococcal programmes acquired as part of the Affinivax Inc
(Affinivax) acquisition, mRNA technology platforms and the phase II
MMR programme.
In the
Specialty Medicines portfolio, there was increased investment in
the early stage research portfolio, particularly CCL17 for osteo
arthritic pain and IL18 for atopic dermatitis and in Jemperli, with preparation for new
phase II/III trials in rectal and colon cancer as well as the
ongoing trials in endometrial cancer. In addition, there was
increased investment in momelotinib, a potential new treatment of
myelofibrosis patients with anaemia, the phase III respiratory
programme for depemokimab, a potential new medicine to treat a
range of eosinophil-driven diseases and for bepirovirsen, the study
in chronic hepatitis B. These increases in investment were partly
offset by decreases related to the completion of late-stage
clinical development programmes for otilimab and Cell & Gene
therapy and reduced R&D investment in Blenrep versus Q1 2022.
|
||||||||
|
|
|
|
|
Q1 2023
|
||||
|
|
|
|
|
|
|
£m
|
AER
|
CER
|
|
Royalty
income
|
Total
|
|
|
|
|
180
|
30%
|
28%
|
|
|
Adjusted
|
|
|
|
|
180
|
30%
|
28%
|
|
|
||||||||
|
Growth
in Total and Adjusted royalty income primarily reflected the
settlement and licensing agreement with Gilead Sciences Inc.
(Gilead) announced on 1 February 2022 and included Gardasil royalty
income of £71 million.
|
||||||||
|
(1)
|
See update on Legal matters on page 29.
|
|
|
|
|
|
Q1 2023
|
||||
|
|
|
|
|
|
|
£m
|
AER
|
CER
|
|
Other
operating (expense)/income
|
Total
|
|
|
|
|
297
|
(50%)
|
(52%)
|
|
|
||||||||
|
The
decrease primarily reflected an unfavourable comparison to the
upfront income in Q1 2022 of £0.9 billion received from the
settlement with Gilead. Net other operating income included an
accounting credit of £271 million (Q1 2022: £335 million
charge) arising from the remeasurement of contingent consideration
liabilities and the liabilities for the Pfizer, Inc. (Pfizer) put
option and Pfizer and Shionogi & Co. Ltd (Shionogi)
preferential dividends in ViiV Healthcare.
|
||||||||
|
|
|
|
|
Q1 2023
|
||||
|
|
|
|
|
|
|
£m
|
AER
|
CER
|
|
Operating
profit
|
Total
|
|
|
|
|
2,082
|
(9%)
|
(15%)
|
|
% of sales
|
|
|
|
|
30.0%
|
(1.9%)
|
(2.4%)
|
|
|
Adjusted
|
|
|
|
|
2,092
|
8%
|
-
|
|
|
|
% of sales
|
|
|
|
|
30.1%
|
3.1%
|
2.5%
|
|
|
||||||||
|
Total
operating profit margin was down 1.9 ppts at AER and 2.4 ppts at
CER primarily reflecting an unfavourable comparison due to the
£0.9 billion upfront income received from the settlement with
Gilead in Q1 2022, partly offset by remeasurement credits on
contingent consideration liabilities.
Adjusted
profit was impacted by lower sales of COVID-19 solutions sales
which led to a drag of 5% AER and CER but increased the Adjusted
operating profit margin by approximately 3.9 ppts at AER and CER.
Excluding COVID-19 Solutions, Adjusted operating profit benefited
from strong sales across all three product areas but margin was
impacted by increased legal charges in the quarter primarily
relating to the Zejula
royalty dispute and an unfavourable comparison to a one-time
benefit from inventory adjustments in Q1 2022.
Contingent
consideration cash payments made to Shionogi and other companies
reduce the balance sheet liability. Total contingent consideration
cash payments in Q1 2023 amounted to £291 million (Q1 2022:
£211 million). These included cash payments made to Shionogi
of £287 million (Q1 2022: £208 million).
|
||||||||
|
|
|
|
|
Q1 2023
|
||||
|
|
|
|
|
|
|
£m
|
AER
|
CER
|
|
Adjusted
operating profit by business
|
Commercial Operations
|
|
|
|
3,375
|
8%
|
1%
|
|
|
% of sales
|
|
|
|
|
48.6%
|
5.2%
|
4.3%
|
|
|
|
R&D
|
|
|
|
|
(1,232)
|
13%
|
6%
|
|
|
||||||||
|
Commercial
Operations Adjusted operating profit reflected lower COVID-19
solutions sales, primarily Xevudy. Sales declined 8% with 19 ppts
AER / 18 ppts CER drag from COVID-19 solutions sales. Operating
profit margin benefitted from product mix upside (with minimal
Xevudy sales) and increased
royalty income, partly offset by increased investment in growth and
launch assets as well as an increase in legal
provisions.
The
R&D segment operating expenses primarily reflected increased
investment in the Vaccines clinical development portfolio,
particularly in pneumococcal programmes, the mRNA technology
platforms and the phase II MMR programme. This was partly offset by
decreases related to the completion of late-stage clinical
development programmes for otilimab and Cell & Gene therapy and
reduced R&D investment in Blenrep versus Q1 2022.
|
||||||||
|
|
|
|
|
Q1 2023
|
||||
|
|
|
|
|
|
|
£m
|
AER
|
CER
|
|
Net
finance costs
|
Total
|
|
|
|
|
174
|
(12%)
|
(16%)
|
|
Adjusted
|
|
|
|
|
170
|
(14%)
|
(18%)
|
|
|
|
||||||||
|
Total net finance costs decreased by £24 million compared to
Q1 2022. Adjusted net finance costs decreased by £28 million
compared to Q1 2022. The decrease is mainly driven by the
net savings from maturing bonds including the Sterling Notes
repurchase in Q4 2022 and higher interest income on
cash.
|
||||||||
|
|
|
|
|
Q1 2023
|
||||
|
|
|
|
|
|
|
£m
|
AER
|
CER
|
|
Taxation
|
Total
|
|
|
|
|
276
|
(15%)
|
(21%)
|
|
Tax rate %
|
|
|
|
|
14.5%
|
|
|
|
|
Adjusted
|
|
|
|
|
303
|
6%
|
(2%)
|
|
|
|
Tax rate %
|
|
|
|
|
15.8%
|
|
|
|
|
||||||||
|
The
effective tax rate impact is broadly in line with expectations for
the quarter. Issues related to taxation are described in Note 14,
‘Taxation’ in the Annual Report 2022. The Group
continues to believe it has made adequate provision for the
liabilities likely to arise from periods that are open and not yet
agreed by relevant tax authorities. The ultimate liability for such
matters may vary from the amounts provided and is dependent upon
the outcome of agreements with relevant tax
authorities.
|
||||||||
|
|
|
|
|
Q1 2023
|
||||
|
|
|
|
|
|
|
£m
|
AER
|
CER
|
|
Non-controlling interests
|
Total
|
|
|
|
|
141
|
(49%)
|
(53%)
|
|
Adjusted
|
|
|
|
|
121
|
(25%)
|
(32%)
|
|
|
|
||||||||
|
The
decrease in Total profit from continuing operations allocated to
non-controlling interest was primarily due to lower allocation of
ViiV Healthcare profits of £140 million (Q1 2022: £227
million), partly offset by decreased credits for remeasurement of
contingent consideration liabilities, as well as lower net profits
in some of the Group’s other entities with non-controlling
interests.
The
decrease in Adjusted profit from continuing operations allocated to
non-controlling interest primarily reflected lower profits in some
of the Group’s entities with non-controlling interests partly
offset by an increased allocation of ViiV Healthcare profits of
£120 million (Q1 2022: £113 million).
|
||||||||
|
|
|
|
|
Q1 2023
|
||||
|
|
|
|
|
|
|
£m
|
AER
|
CER
|
|
Earnings per share
|
Total
|
|
|
|
|
36.8p
|
(1%)
|
(8%)
|
|
Adjusted
|
|
|
|
|
37.0p
|
15%
|
7%
|
|
|
|
||||||||
|
The
decrease in Total EPS primarily reflected an unfavourable
comparison due to upfront income received from the settlement with
Gilead in Q1 2022. This was partly offset by remeasurement credits
for contingent consideration liabilities compared to charges in Q1
2022, lower non-controlling interests and lower effective tax
rate.
Adjusted
EPS reflected strong growth in sales across all product areas
excluding COVID-19 solutions, higher royalty income, lower
non-controlling interests and a lower effective tax rate. This was
partly offset by increased legal charges primarily relating to
royalties and investment behind launches in Specialty Medicines
including HIV and Vaccines plus higher supply chain costs, freight
and distribution costs. Decline in lower margin COVID-19 solutions
sales was a drag on Adjusted EPS growth of 7 ppts at AER and
CER.
|
||||||||
|
Currency impact on Q1 2023 results
The
results for Q1 2023 are based on average exchange rates,
principally £1/$1.22, £1/€1.14 and £1/Yen 162.
Comparative exchange rates are given on page 31. The period-end
exchange rates were £1/$1.24, £1/€1.14 and
£1/Yen 165.
In Q1
2023, turnover was down 3% at AER and 8% at CER. Total EPS from
continuing operations was 36.8p compared with 37.3p in Q1 2022.
Adjusted EPS was 37.0p compared with 32.3p in Q1 2022, up 15% at
AER and 7% at CER. The favourable currency impact primarily
reflected the weakening of Sterling against the US Dollar and the
Euro. Exchange gains or losses on the settlement of intercompany
transactions had a one percent adverse impact on the eight
percentage point favourable currency impact on Adjusted
EPS.
|
|
Cash generation
|
|
Cash flow
|
|
|
|
|
Q1 2023
£m
|
|
Q1
2022
£m
|
|
|
|
|
|
|
|
|
Cash
generated from operations attributable to
continuing
operations (£m)
|
|
|
287
|
|
2,352
|
|
Cash
generated from operations attributable to
discontinued
operations (£m)
|
|
|
-
|
|
403
|
|
|
|
|
|
|
|
|
Total
cash generated from operations (£m)
|
|
|
287
|
|
2,755
|
|
|
|
|
|
|
|
|
Net
cash inflow/(outflow) from operating activities from
continuing
operations (£m)
|
|
|
53
|
|
2,206
|
|
Net
cash inflow/(outflow) from operating activities from
discontinued
operations (£m)
|
|
|
-
|
|
336
|
|
|
|
|
|
|
|
|
Total
net cash generated from operating activities (£m)
|
|
|
53
|
|
2,542
|
|
|
|
|
|
|
|
|
Free
cash inflow/(outflow) from continuing operations*
(£m)
|
|
|
(689)
|
|
1,477
|
|
Free
cash flow from continuing operations growth (%)
|
|
|
>(100)%
|
|
|
|
Free
cash flow conversion from continuing operations* (%)
|
|
|
3%
|
|
96%
|
|
Total
net debt** (£m)
|
|
|
(17,950)
|
|
(19,351)
|
|
|
|
|
|
|
|
|
*
|
Free cash flow from continuing operations and free cash flow
conversion are defined on page 44.
|
|
**
|
Net debt is analysed on page 34.
|
|
Q1 2023
Cash
generated from operating activities from continuing operations was
£287 million (Q1 2022: £2,352 million). The decrease
primarily reflected an unfavourable comparison due to the upfront
income from the settlement with Gilead received in Q1 2022,
unfavourable timing of profit share payments for Xevudy, increase in seasonal inventory
and lower payable balances reflecting increased investment in
2022.
Total
cash payments to Shionogi in relation to the ViiV Healthcare
contingent consideration liability in the quarter were £287
million (Q1 2022: £208 million), all of which was recognised
in cash flows from operating activities. These payments are
deductible for tax purposes.
Free cash outflow was £689 million for the quarter (Q1 2022:
£1,477 million inflow). The decrease primarily reflected an
unfavourable comparison due to the upfront income from the
settlement with Gilead received in Q1 2022, unfavourable timing of
profit share payments for Xevudy, increase in seasonal inventory, lower payable
balances reflecting increased investment in 2022 and higher tax
payments.
|
|
Total Net debt
At 31
March 2023, net debt was £17,950 million, compared with
£17,197 million at 31 December 2022, comprising gross debt of
£20,905 million and cash and liquid investments of £2,955
million.
Net
debt increased by £0.8 billion primarily due to £0.7
billion free cash outflow and dividends paid to shareholders of
£0.6 billion. This was partly offset by net favourable
exchange impacts of £0.4 billion from the translation of
non-Sterling denominated debt and exchange on other financing items
and £0.1 billion of income received from equity
investments.
At 31
March 2023, GSK had short-term borrowings (including overdrafts and
lease liabilities) repayable within 12 months of £4,261
million with loans of £1,682 million repayable in the
subsequent year.
|
|
Q1 2023 pipeline highlights (since 1 February 2023)
|
|
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
Regulatory approvals or other regulatory action
|
Jesduvroq
|
ASCEND-D (anaemia of chronic kidney disease on
dialysis)
|
Regulatory approval (US)
|
|
Jemperli
|
GARNET (2L endometrial cancer)
|
Conversion to regular (full) approval (US)
|
|
|
Regulatory submissions or acceptances
|
Nucala
|
Severe asthma
|
Regulatory acceptance (CN)
|
|
Jemperli
|
RUBY (1L mismatch repair-deficient/microsatellite instability-high
(dMMR/MSI-H) endometrial cancer)
|
Regulatory acceptance (EU)
|
|
|
Phase III data readouts or other significant events
|
Benlysta
|
Paediatric systemic lupus erythematosus (sub-cutaneous
administration)
|
Positive phase II data readout
|
|
Jemperli
|
Rectal cancer
|
US FDA Advisory Committee vote to support phase II trial
design
|
|
|
Jemperli
|
RUBY (1L endometrial cancer)
|
Phase III data presentation
|
|
|
gepotidacin
|
EAGLE-2/3 (uncomplicated urinary tract infection)
|
Phase III data presentation
|
|
|
RSV older adult vaccine candidate
|
RSV, older adults aged
60+ years
|
US FDA Advisory Committee vote
|
|
|
MenABCWY (gen 1)
vaccine candidate
|
Meningitis ABCWY
|
Positive phase III data readout
|
|
Anticipated news flow
|
|
Timing
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
H1 2023
|
daprodustat
|
ASCEND (anaemia of chronic kidney disease)
|
Regulatory decision
(EU)
|
|
Jemperli
|
RUBY (1L endometrial cancer)
|
Regulatory submission
(US)
|
|
|
momelotinib
|
MOMENTUM (myelofibrosis with anaemia)
|
Regulatory decision (US)
|
|
|
RSV older adult vaccine candidate
|
RSV, older adults aged
60+ years
|
Regulatory decision (US)
|
|
|
Shingrix
|
Shingles, at-risk adults aged 18+ years
|
Regulatory decision (JP)
|
|
|
H2 2023
|
bepirovirsen
|
B-Together (hepatitis B virus)
|
Phase IIb data readout
|
|
Nucala
|
Nasal polyposis
|
Regulatory submission
(CN, JP)
|
|
|
Blenrep
|
DREAMM-7 (2L+ multiple myeloma)
|
Phase III data readout
|
|
|
Blenrep
|
DREAMM-8 (2L+ multiple myeloma)
|
Phase III data readout
|
|
|
Blenrep
|
DREAMM-7 (2L+ multiple myeloma)
|
Regulatory submission
(US, EU)
|
|
|
Blenrep
|
DREAMM-8 (2L+ multiple myeloma)
|
Regulatory submission
(US, EU)
|
|
|
Jemperli
|
RUBY (1L endometrial cancer)
|
Regulatory decision
(US)
|
|
|
Zejula
|
FIRST (1L maintenance ovarian cancer)
|
Phase III data readout
|
|
|
cabotegravir
|
Pre-exposure prophylaxis, long-acting injectable
|
Regulatory decision (EU)
|
|
|
Vocabria
|
HIV
|
Regulatory decision (CN)
|
|
|
gepotidacin
|
EAGLE-1 (urogenital gonorrhoea)
|
Phase III data readout
|
|
|
gepotidacin
|
EAGLE-2/3 (uncomplicated urinary tract infection)
|
Regulatory submission (EU)
|
|
|
MenABCWY (gen 2)
vaccine candidate
|
Meningitis ABCWY
|
Phase II data readout
|
|
|
RSV older adult vaccine candidate
|
RSV, older adults aged
60+ years
|
Regulatory decision
(EU, JP)
|
|
|
RSV older adult vaccine candidate
|
RSV, older adults aged
50-59 years
|
Phase III data readout
|
|
|
RSV older adult vaccine candidate
|
RSV, older adults aged
50-59 years
|
Regulatory submission
(US, EU, JP)
|
|
|
SKYCovione COVID-19
vaccine
|
COVID-19
|
Regulatory decision (EU)
|
|
|
2024
|
linerixibat
|
GLISTEN (cholestatic pruritus in primary biliary
cholangitis)
|
Phase III data readout
|
|
linerixibat
|
GLISTEN (cholestatic pruritus in primary biliary
cholangitis)
|
Regulatory submission
(US, EU)
|
|
|
Nucala
|
Severe asthma
|
Regulatory decision (CN)
|
|
|
Nucala
|
Nasal polyposis
|
Regulatory decision (JP)
|
|
|
Nucala
|
MATINEE (chronic obstructive pulmonary disease)
|
Phase III data readout
|
|
|
Nucala
|
MATINEE (chronic obstructive pulmonary disease)
|
Regulatory submission
(US, EU, CN, JP)
|
|
|
Blenrep
|
DREAMM-7 (2L+ multiple myeloma)
|
Regulatory decision
(US, EU)
|
|
|
Blenrep
|
DREAMM-8 (2L+ multiple myeloma)
|
Regulatory decision
(US, EU)
|
|
|
cobolimab
|
COSTAR (non-small cell lung cancer)
|
Phase III data readout
|
|
|
Jemperli
|
RUBY (1L dMMR/MSI-H endometrial cancer)
|
Regulatory decision (EU)
|
|
|
Jemperli
|
RUBY part 2 (1L endometrial cancer)
|
Phase III data readout
|
|
|
Jemperli
|
RUBY part 2 (1L endometrial cancer)
|
Regulatory submission
(US, EU)
|
|
|
momelotinib
|
MOMENTUM (myelofibrosis with anaemia)
|
Regulatory decision (EU)
|
|
|
Zejula
|
ZEAL (1L maintenance NSCLC)
|
Phase III data readout
|
|
|
gepotidacin
|
EAGLE-2/3 (uncomplicated urinary tract infection)
|
Regulatory decision
(US, EU)
|
|
|
gepotidacin
|
EAGLE-2/3 (uncomplicated urinary tract infection)
|
Regulatory submission
(JP)
|
|
|
gepotidacin
|
EAGLE-1 (urogenital gonorrhoea)
|
Regulatory submission
(US)
|
|
|
MenABCWY (gen 1)
vaccine candidate
|
Meningitis ABCWY
|
Regulatory submission (US)
|
|
|
RSV older adult vaccine candidate
|
RSV, older adults aged
50-59 years
|
Regulatory decision
(US, EU, JP)
|
|
Refer
to pages 35 to 43 for further details on several key medicines and
vaccines in development by therapy area.
|
|
Trust: progress on our six
priority areas for responsible business
Building
Trust by operating responsibly is integral to GSK’s strategy
and culture. This will support growth and returns to shareholders,
reduce risk, and help GSK’s people thrive while delivering
sustainable health impact at scale. The Company has identified six
Environmental, Social, and Governance (ESG) focus areas that
address what is most material to GSK’s business and the
issues that matter the most to its stakeholders. Highlights below
include activity since Full-year and Q4 2022 results. For a full
list of progress in 2022, please see the 2022 ESG Performance
Report at:
https://gsk.to/3V1hwFk.
Access
Commitment:
to make GSK’s vaccines and medicines available at value-based
prices that are sustainable for the business and implement access
strategies that increase the use of GSK’s vaccines and
medicines to treat and protect underserved people.
|
|
Progress to date:
|
|
●
|
GSK
continues to collaborate to support access to its HIV portfolio.
For example, following the signing of a voluntary licensing
agreement for cabotegravir for HIV pre-exposure prophylaxis (PrEP)
between ViiV Healthcare and the Medicines Patent Pool (MPP) in July
2022, the MPP signed subsequent sub-licence agreements in March
2023 with Aurobindo Pharma Limited, Cipla, Inc. and Viatris, Inc.
– through its subsidiary Mylan – to manufacture generic
versions of cabotegravir long-acting for PrEP. More information can
be found at: https://gsk.to/3LsG72L.
|
|
|
|
|
●
|
Working
with GSK’s partners, more than 1.2 million children in Ghana,
Kenya and Malawi have received at least one dose of the
Company’s malaria vaccine, Mosquirix (RTS,S/AS01 E). In March
2023, Kenya expanded vaccine use beyond the communities involved in
the Malaria Vaccine Immunisation Programme (MVIP), almost doubling
the number of areas where children can access it. All three
countries that were part of the MVIP have now expanded the
rollout.
|
|
Global health and health
security
Commitment: develop novel products and technologies to treat
and prevent priority diseases, including pandemic
threats.
|
|
Progress to date:
|
|
●
|
GSK
remains committed to innovation across medicines and vaccines to
help get ahead of antimicrobial resistance, with a number of
R&D projects targeting pathogens deemed ‘critical’
or ‘urgent’ by the WHO and US Centers for Disease
Control and Prevention. GSK reinforced its commitment to developing
new antibiotics in high unmet medical need areas when it presented
positive results from the pivotal EAGLE-2 and EAGLE-3 phase III
trials for gepotidacin, an investigational, first-in-class oral
antibiotic with a novel mechanism of action for uncomplicated
urinary tract infections (uUTI) in female adults and adolescents.
Escherichia coli (e. coli) bacteria are the main cause of uUTI but
it is showing increasing resistance to antibiotics currently
used(1).
The data were disclosed in an oral presentation at the European
Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
in Copenhagen, Denmark. More information can be found at:
https://gsk.to/40yA5lq.
|
|
|
|
|
●
|
GSK
continued to expand its industry-leading infectious diseases
portfolio. In March 2023, the Company entered an exclusive licence
agreement for Brexafemme
(ibrexafungerp tablets), a US FDA-approved, first-in-class
antifungal for treating vulvovaginal candidiasis and for a
reduction in the incidence of recurrent VVC. Brexafemme complements GSK’s
late-stage antibiotics gepotidacin, and tebipenem, a potential new
treatment for complicated urinary tract infections. With rates of
multi-drug resistant fungal infections rising, this agreement
strengthens the Company’s position as an innovation leader in
antimicrobial resistance. More information can be found at:
https://gsk.to/3oHAlkx.
|
|
Environment
Commitment: committed to a net zero, nature-positive,
healthier planet with ambitious goals set for 2030 and
2045.
|
|
Progress to date:
|
|
●
|
The
Company has clear and measurable targets to achieve its climate and
nature goals and shared its annual progress as part of GSK’s
ESG Performance Report. The Company also published more detail on
its carbon reduction pathway and use of carbon credits, which can
be found at: https://gsk.to/3LtovDT.
|
|
|
|
|
●
|
The
Taskforce on Nature-related Financial Disclosures (TNFD) recently
released its final beta framework for nature-related risk
management and disclosure. GSK sits on the Taskforce, and to pilot
the recommendations ahead of the final framework expected later
this year, the Company made an initial disclosure, focusing on
strategy, metrics and targets in its 2022 Annual Report (page 62).
In addition, GSK was included in the TNFD (section 3.1) scenario
guidance as an example of a multinational company taking an
advanced approach.
|
|
Diversity, equity and
inclusion
Commitment: create a diverse, equitable and inclusive
workplace; enhance recruitment of diverse patient populations in
GSK clinical trials; and support diverse communities.
|
|
Progress to date:
|
|
●
|
Appropriate
clinical research representation is critical for advancing the
Company’s understanding of new vaccines and medicines to
ensure they positively impact patients' lives. GSK announced
results from a 17-year retrospective study on US clinical trial
diversity in February 2023. Results of the study demonstrate
real-world disease epidemiology data, compared to the conventional
standard of US Census data, is a better benchmark to ensure
clinical trial enrolment reflects the populations affected by
diseases. GSK has committed to applying insights from the study and
collaborating with regulators, patients, academics, and other
biopharmaceutical companies to make meaningful progress on clinical
trial diversity. As a result, 100% of phase III trials now include
a demographic plan. More information can be found at:
https://gsk.to/40IAGkE.
|
||
|
|
|
|
|
|
●
|
GSK is
committed to equality of representation so that its workforce
reflects the communities in which it operates and hires, and that
GSK leadership reflects the Company’s workforce. In February
2023, GSK communicated its 2022 progress which was also highlighted
in the ESG Performance Report:
|
||
|
|
|
|
|
|
|
-
|
Women
held 42% of Vice President (VP) and above roles globally, compared
with 40% in 2021, bringing the Company closer to its 2025
aspirational target of 45%; Women made up 47% of all employees in
2022 and 50% of all management roles.
|
|
|
|
|
|
|
|
|
-
|
In the
US, GSK has 31.3% of ethnically diverse leaders at the VP level and
above and has met its 2025 aspirational target of at least
30%.
|
|
|
|
|
|
|
|
|
-
|
In the
UK, the Company has 14.3% of ethnically diverse leaders at VP and
above, progressing towards its 2025 aspirational target of reaching
at least 18%.
|
|
|
Ethical
standards
Commitment: promote ethical behaviour across GSK’s
business by supporting its employees to do the right thing and
working with suppliers that share the Company’s standards and
operate responsibly.
|
|
●
|
Performance
metrics related to ethical standards are updated annually with
details from the most recent year on page 26 of GSK’s ESG
Performance Report 2022.
|
|
Product
governance
Commitment: maintain robust quality and safety processes and
responsibly use data and new technologies.
|
|
●
|
Performance
metrics related to product governance are updated annually with
details from the most recent year on page 30 of GSK’s ESG
Performance Report 2022.
|
|
ESG rating
performance
Detailed
below is how GSK performs in key ESG ratings.
|
|
External benchmark
|
2020
|
2021
|
2022
|
Comments
|
|
S&P
Global’s Corporate Sustainability Assessment(2)
|
87
2nd in
Pharma industry
|
88
1st in
Pharma industry
|
86
2nd in
Pharma industry(2)
|
|
|
Access
to Medicines Index
|
4.23
Ranked
1st
|
n/a
|
4.06
Ranked
1st
|
Led the
bi-annual index since its inception in 2008
|
|
Antimicrobial
resistance benchmark
|
86%
Ranked
1st
|
84%
Ranked
1st
|
n/a
|
Led the
bi-annual benchmark since inception
|
|
CDP
Climate Change
|
A-
|
A-
|
A-
|
|
|
CDP
Water Security
|
A
|
B
|
B
|
|
|
CDP
Forests(3)
(palm oil)
|
n/a
|
B
|
A-
|
|
|
CDP
Forests(3)
(timber)
|
n/a
|
B
|
B
|
|
|
CDP
supplier engagement rating
|
Leader
|
Leader
|
Leader
|
|
|
Sustainalytics
|
21.3
8th in
Pharma
sub-industry
group
|
18.9
5th in
Pharma sub-industry group
|
18.8
3rd in
Pharma sub-industry group
|
Lower
score represents lower risk
|
|
MSCI
|
AA
|
AA
|
AA
|
|
|
Moody’s
ESG solutions
|
62
2nd in
Pharma and Biotech sector
|
61
2nd in
Pharma and Biotech sector
|
n/a
|
|
|
ISS
Corporate Rating
|
B
|
B+
|
B+
|
|
|
FTSE4Good
|
Member
|
Member
|
Member
|
Member
since 2004
|
|
ShareAction’s
Workforce Disclosure Initiative (WDI)
|
68%
Sector
average: 65%
|
75%
Sector
average: 70%
|
77%
Sector
average: 66%
|
|
|
(1)
|
WHO. Global priority list of
antibiotic-resistant bacteria to guide research, discovery, and
development of new antibiotics. 2017; CDC. Antibiotic resistance
threats in the United States. 2019. Available from:
https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
(Accessed October 2022)
|
|
(2)
|
As at 31 March
2023.
|
|
(3)
|
CDP Forests assessments introduced
in 2021.
|
|
Contents
|
Page
|
|
Q1 2023
pipeline highlights
|
11
|
|
ESG
|
13
|
|
Total
and Adjusted results
|
16
|
|
Income
statement
|
21
|
|
Statement
of comprehensive income
|
22
|
|
Balance
sheet
|
23
|
|
Statement
of changes in equity
|
24
|
|
Cash
flow statement – three months ended 31 March
2023
|
25
|
|
Sales
tables – three months ended 31 March 2023
|
26
|
|
Segment
information
|
28
|
|
Legal
matters
|
29
|
|
Returns
to shareholders
|
30
|
|
Additional
information
|
31
|
|
Net
assets
|
32
|
|
Discontinued
operations
|
33
|
|
Reconciliation
of cash flow to movements in net debt
|
34
|
|
Net
debt analysis
|
34
|
|
Free
cash flow reconciliation
|
34
|
|
R&D
commentary
|
35
|
|
Reporting
definitions
|
44
|
|
Guidance,
assumptions and cautionary statements
|
45
|
|
Independent
Auditor’s review report to GSK plc
|
47
|
|
Contacts
|
|
GSK plc
(LSE/NYSE:GSK) is a global biopharma company with a purpose to
unite science, technology, and talent to get ahead of disease
together. Find out more at
www.gsk.com.
|
|
GSK enquiries:
|
|
|
|
|
Media
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington)
|
|
|
|
|
|
|
Investor
Relations
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
7881 269066
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Joshua
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
589 3774
|
(Philadelphia)
|
|
|
Frances
De Franco
|
+1 215
751 4855
|
(Philadelphia)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Registered in England & Wales:
No.
3888792
|
|||
|
|
|||
|
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
|
|||
|
Total and Adjusted
results
|
|
Total
reported results represent the Group’s overall
performance.
GSK
also uses a number of adjusted, non-IFRS, measures to report the
performance of its business. Adjusted results and other non-IFRS
measures may be considered in addition to, but not as a substitute
for or superior to, information presented in accordance with IFRS.
Adjusted results are defined below and other non-IFRS measures are
defined on page 44.
GSK
believes that Adjusted results, when considered together with Total
results, provide investors, analysts and other stakeholders with
helpful complementary information to understand better the
financial performance and position of the Group from period to
period, and allow the Group’s performance to be more easily
compared against the majority of its peer companies. These measures
are also used by management for planning and reporting purposes.
They may not be directly comparable with similarly described
measures used by other companies.
GSK
encourages investors and analysts not to rely on any single
financial measure but to review GSK’s quarterly results
announcements, including the financial statements and notes, in
their entirety.
GSK is
committed to continuously improving its financial reporting, in
line with evolving regulatory requirements and best practice. In
line with this practice, GSK expects to continue to review and
refine its reporting framework.
Adjusted
results exclude the profits from discontinued operations from the
Consumer Healthcare business (see details on page 33) and the
following items in relation to our continuing operations from Total
results, together with the tax effects of all of these
items:
|
|
●
|
amortisation
of intangible assets (excluding computer software and capitalised
development costs)
|
|
●
|
impairment
of intangible assets (excluding computer software) and
goodwill
|
|
●
|
major
restructuring costs, which include impairments of tangible assets
and computer software, (under specific Board approved programmes
that are structural, of a significant scale and where the costs of
individual or related projects exceed £25 million), including
integration costs following material acquisitions
|
|
●
|
transaction-related
accounting or other adjustments related to significant
acquisitions
|
|
●
|
proceeds
and costs of disposal of associates, products and businesses;
significant settlement income; significant legal charges (net of
insurance recoveries) and expenses on the settlement of litigation
and government investigations; other operating income other than
royalty income, and other items
|
|
Costs
for all other ordinary course smaller scale restructuring and legal
charges and expenses from continuing operations are retained within
both Total and Adjusted results.
As
Adjusted results include the benefits of Major restructuring
programmes but exclude significant costs (such as significant
legal, major restructuring and transaction items) they should not
be regarded as a complete picture of the Group’s financial
performance, which is presented in Total results. The exclusion of
other Adjusting items may result in Adjusted earnings being
materially higher or lower than Total earnings. In particular, when
significant impairments, restructuring charges and legal costs are
excluded, Adjusted earnings will be higher than Total
earnings.
GSK has
undertaken a number of Major restructuring programmes in response
to significant changes in the Group’s trading environment or
overall strategy or following material acquisitions. Within the
Pharmaceuticals sector, the highly regulated manufacturing
operations and supply chains and long lifecycle of the business
mean that restructuring programmes, particularly those that involve
the rationalisation or closure of manufacturing or R&D sites
are likely to take several years to complete. Costs, both cash and
non-cash, of these programmes are provided for as individual
elements are approved and meet the accounting recognition criteria.
As a result, charges may be incurred over a number of years
following the initiation of a Major restructuring
programme.
Significant
legal charges and expenses are those arising from the settlement of
litigation or government investigations that are not in the normal
course and materially larger than more regularly occurring
individual matters. They also include certain major legacy
matters.
Reconciliations
between Total and Adjusted results, providing further information
on the key Adjusting items, are set out on pages 18 and
19.
GSK
provides earnings guidance to the investor community on the basis
of Adjusted results. This is in line with peer companies and
expectations of the investor community, supporting easier
comparison of the Group’s performance with its peers. GSK is
not able to give guidance for Total results as it cannot reliably
forecast certain material elements of the Total results,
particularly the future fair value movements on contingent
consideration and put options that can and have given rise to
significant adjustments driven by external factors such as currency
and other movements in capital markets.
|
|
ViiV Healthcare
ViiV
Healthcare is a subsidiary of the Group and 100% of its operating
results (turnover, operating profit, profit after tax) are included
within the Group income statement.
Earnings
are allocated to the three shareholders of ViiV Healthcare on the
basis of their respective equity shareholdings (GSK 78.3%, Pfizer
11.7% and Shionogi 10%) and their entitlement to preferential
dividends, which are determined by the performance of certain
products that each shareholder contributed. As the relative
performance of these products changes over time, the proportion of
the overall earnings allocated to each shareholder also changes. In
particular, the increasing proportion of sales of dolutegravir and
cabotegravir-containing products has a favourable impact on the
proportion of the preferential dividends that is allocated to GSK.
Adjusting items are allocated to shareholders based on their equity
interests. GSK was entitled to approximately 83% of the Total
earnings and 82% of the Adjusted earnings of ViiV Healthcare for
2022.
As
consideration for the acquisition of Shionogi’s interest in
the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi
received the 10% equity stake in ViiV Healthcare and ViiV
Healthcare also agreed to pay additional future cash consideration
to Shionogi, contingent on the future sales performance of the
products being developed by that joint venture, dolutegravir and
cabotegravir. Under IFRS 3 ‘Business combinations’, GSK
was required to provide for the estimated fair value of this
contingent consideration at the time of acquisition and is required
to update the liability to the latest estimate of fair value at
each subsequent period end. The liability for the contingent
consideration recognised in the balance sheet at the date of
acquisition was £659 million. Subsequent remeasurements are
reflected within other operating income/(expense) and within
Adjusting items in the income statement in each
period.
Cash
payments to settle the contingent consideration are made to
Shionogi by ViiV Healthcare each quarter, based on the actual sales
performance and other income of the relevant products in the
previous quarter. These payments reduce the balance sheet liability
and hence are not recorded in the income statement. The cash
payments made to Shionogi by ViiV Healthcare in Q1 2023 were
£287 million.
As the
liability is required to be recorded at the fair value of estimated
future payments, there is a significant timing difference between
the charges that are recorded in the Total income statement to
reflect movements in the fair value of the liability and the actual
cash payments made to settle the liability.
Further
explanation of the acquisition-related arrangements with ViiV
Healthcare are set out on pages 71 and 72 of the Annual Report
2022.
|
|
Adjusting items
The
reconciliations between Total results and Adjusted results for Q1
2023 and Q1 2022 are set out below.
|
|
Three months ended 31 March 2023
|
|
|
Total
results
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Divest-
ments,
significant
legal
and
other
items
£m
|
|
Adjusted
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
6,951
|
|
|
|
|
|
|
|
|
|
|
|
6,951
|
|
Cost of
sales
|
(1,943)
|
|
151
|
|
|
|
35
|
|
|
|
5
|
|
(1,752)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
5,008
|
|
151
|
|
|
|
35
|
|
|
|
5
|
|
5,199
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,143)
|
|
|
|
|
|
69
|
|
|
|
9
|
|
(2,065)
|
|
Research
and development
|
(1,260)
|
|
18
|
|
16
|
|
4
|
|
|
|
|
|
(1,222)
|
|
Royalty
income
|
180
|
|
|
|
|
|
|
|
|
|
|
|
180
|
|
Other
operating income/(expense)
|
297
|
|
|
|
|
|
|
|
(271)
|
|
(26)
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
2,082
|
|
169
|
|
16
|
|
108
|
|
(271)
|
|
(12)
|
|
2,092
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance cost
|
(174)
|
|
|
|
|
|
|
|
|
|
4
|
|
(170)
|
|
Share
of after tax profit/(loss) of associates
and
joint venture
|
(2)
|
|
|
|
|
|
|
|
|
|
|
|
(2)
|
|
Profit/(loss)
on disposal of interest in associates
|
1
|
|
|
|
|
|
|
|
|
|
(1)
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
1,907
|
|
169
|
|
16
|
|
108
|
|
(271)
|
|
(9)
|
|
1,920
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(276)
|
|
(36)
|
|
(4)
|
|
(22)
|
|
15
|
|
20
|
|
(303)
|
|
Tax rate %
|
14.5%
|
|
|
|
|
|
|
|
|
|
|
|
15.8%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation from continuing
operations
|
1,631
|
|
133
|
|
12
|
|
86
|
|
(256)
|
|
11
|
|
1,617
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to non-controlling
interests from continuing operations
|
141
|
|
-
|
|
-
|
|
-
|
|
(20)
|
|
-
|
|
121
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to shareholders from
continuing operations
|
1,490
|
|
133
|
|
12
|
|
86
|
|
(236)
|
|
11
|
|
1,496
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,631
|
|
133
|
|
12
|
|
86
|
|
(256)
|
|
11
|
|
1,617
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from continuing operations
|
36.8p
|
|
3.3p
|
|
0.3p
|
|
2.1p
|
|
(5.8)p
|
|
0.3p
|
|
37.0p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares (millions)
|
4,044
|
|
|
|
|
|
|
|
|
|
|
|
4,044
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended 31 March 2022(a)
|
|
|
Total
results
£m
|
|
Profit
from
discon-
tinued
operations
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Divest-
ments,
significant
legal
and
other
items
£m
|
|
Adjusted
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
7,190
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,190
|
|
Cost of
sales
|
(2,717)
|
|
|
|
163
|
|
|
|
15
|
|
12
|
|
|
|
(2,527)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
4,473
|
|
|
|
163
|
|
|
|
15
|
|
12
|
|
|
|
4,663
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(1,812)
|
|
|
|
|
|
|
|
28
|
|
|
|
14
|
|
(1,770)
|
|
Research
and development
|
(1,103)
|
|
|
|
23
|
|
(16)
|
|
8
|
|
|
|
|
|
(1,088)
|
|
Royalty
income
|
138
|
|
|
|
|
|
|
|
|
|
|
|
|
|
138
|
|
Other
operating income/(expense)
|
597
|
|
|
|
|
|
|
|
|
|
335
|
|
(932)
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
2,293
|
|
|
|
186
|
|
(16)
|
|
51
|
|
347
|
|
(918)
|
|
1,943
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance cost
|
(198)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(198)
|
|
Share
of after tax profit/(loss) of associates and joint
venture
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
2,094
|
|
|
|
186
|
|
(16)
|
|
51
|
|
347
|
|
(918)
|
|
1,744
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(323)
|
|
|
|
(39)
|
|
3
|
|
(12)
|
|
(53)
|
|
137
|
|
(287)
|
|
Tax rate %
|
15.4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.5%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation from
continuing operations
|
1,771
|
|
|
|
147
|
|
(13)
|
|
39
|
|
294
|
|
(781)
|
|
1,457
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
after taxation from
discontinued
operations and other
gains/(losses)
from the demerger
|
396
|
|
(396)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation from
discontinued operations
|
396
|
|
(396)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit after taxation
for the period
|
2,167
|
|
(396)
|
|
147
|
|
(13)
|
|
39
|
|
294
|
|
(781)
|
|
1,457
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling
interest
from continuing operations
|
275
|
|
|
|
|
|
|
|
|
|
(114)
|
|
|
|
161
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to shareholders
from
continuing operations
|
1,496
|
|
|
|
147
|
|
(13)
|
|
39
|
|
408
|
|
(781)
|
|
1,296
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling
interest
from discontinued
operations
|
90
|
|
(90)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to shareholders
from
discontinued operations
|
306
|
|
(306)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,167
|
|
(396)
|
|
147
|
|
(13)
|
|
39
|
|
294
|
|
(781)
|
|
1,457
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit attributable to
non-controlling interests
|
365
|
|
(90)
|
|
|
|
|
|
|
|
(114)
|
|
|
|
161
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit attributable to
shareholders
|
1,802
|
|
(306)
|
|
147
|
|
(13)
|
|
39
|
|
408
|
|
(781)
|
|
1,296
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,167
|
|
(396)
|
|
147
|
|
(13)
|
|
39
|
|
294
|
|
(781)
|
|
1,457
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from continuing
operations
|
37.3p
|
|
|
|
3.7p
|
|
(0.3)p
|
|
1.0p
|
|
10.2p
|
|
(19.6)p
|
|
32.3p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from
discontinued
operations
|
7.6p
|
|
(7.6)p
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total earnings per share
|
44.9p
|
|
(7.6)p
|
|
3.7p
|
|
(0.3)p
|
|
1.0p
|
|
10.2p
|
|
(19.6)p
|
|
32.3p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number
of
shares (millions)
|
4,016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
The Q1 2022 comparative results
have been restated on a consistent basis from those previously
published to reflect the demerger of the Consumer Healthcare
business
(see page 33) and the impact of
Share Consolidation implemented on 18 July 2022 (see page
33).
|
|
Major restructuring
and integration
|
|
Total
Major restructuring charges from continuing operations incurred in
Q1 2023 were £108 million (Q1 2022: £51 million),
analysed as follows:
|
|
|
Q1 2023
|
|
Q1
2022
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Separation
Preparation restructuring
programme
|
37
|
|
47
|
|
84
|
|
11
|
|
37
|
|
48
|
|
Significant
acquisitions
|
21
|
|
1
|
|
22
|
|
-
|
|
-
|
|
-
|
|
Legacy
programmes
|
-
|
|
2
|
|
2
|
|
2
|
|
1
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
58
|
|
50
|
|
108
|
|
13
|
|
38
|
|
51
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The
Separation Preparation programme incurred cash charges of £37
million primarily from the restructuring of some administrative
functions as well as Global Supply Chain and R&D. The non-cash
charges of £47 million primarily reflected the write-down of
assets in administrative as well as manufacturing
locations.
|
|
The
benefit in Q1 2023 from restructuring programmes was £0.1
billion, primarily relating to the Separation Preparation
restructuring programme. The programme has delivered £0.9
billion of annual savings to date and targets to deliver £1.0
billion by 2023, with total costs estimated at £2.4 billion,
of which £1.6 billion is expected to be cash
costs.
Costs
of significant acquisitions relate to integration costs of Sierra
Oncology Inc. (Sierra) and Affinivax which were acquired in Q3
2022.
|
|
Transaction-related adjustments
Transaction-related
adjustments from continuing operations resulted in a net credit of
£271 million (Q1 2022: £347 million charge) all of which
related to accounting (credits)/charge for the remeasurement of
contingent consideration liabilities and the liabilities for the
Pfizer put option and Pfizer and Shionogi preferential dividends in
ViiV Healthcare.
|
|
Charge/(credit)
|
Q1 2023
£m
|
|
Q1
2022
£m
|
|
|
|
|
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint
Venture
(including
Shionogi preferential dividends)
|
(64)
|
|
256
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
(105)
|
|
32
|
|
Contingent
consideration on former Novartis Vaccines business
|
(69)
|
|
44
|
|
Contingent
consideration on acquisition of Affinivax
|
(33)
|
|
-
|
|
Other
adjustments
|
-
|
|
15
|
|
|
|
|
|
|
Total
transaction-related charges
|
(271)
|
|
347
|
|
|
|
|
|
|
The £64 million credit relating to the contingent
consideration for the former Shionogi-ViiV Healthcare joint venture
represented a reduction in the valuation of the contingent
consideration due to Shionogi, as a result of a credit of £172
million primarily from exchange rates as well as sales forecasts,
partly offset by the unwind of the discount for £108 million.
The £105 million credit relating to the ViiV Healthcare put
option and Pfizer preferential dividends represented a reduction in
the valuation of the put option primarily as a result of updated
exchange rates as well as updated sales forecasts and lower cash
balances.
The
ViiV Healthcare contingent consideration liability is fair valued
under IFRS. An explanation of the accounting for the
non-controlling interests in ViiV Healthcare is set out on page
17.
The £69 million credit relating to the contingent
consideration on the former Novartis Vaccines business primarily
relates to changes to future sales forecasts.
Divestments, significant legal charges, and other
items
Divestments, significant legal charges and other items primarily
included dividend and distribution income received from investments
partly offset by fair value loss of £65 million on the
retained stake in Haleon.
|
|
Financial
information
|
|
Income statements
|
|
|
|
|
|
Q1 2023
£m
|
|
Q1
2022(a)
£m
|
|
|
|
|
|
|
|
|
|
|
| TURNOVER |
|
|
|
6,951
|
|
7,190
|
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
|
|
|
(1,943)
|
|
(2,717)
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
|
|
|
5,008
|
|
4,473
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
|
|
|
(2,143)
|
|
(1,812)
|
|
|
Research
and development
|
|
|
|
(1,260)
|
|
(1,103)
|
|
|
Royalty income
|
|
|
|
180
|
|
138
|
|
|
Other
operating income/(expense)
|
|
|
|
297
|
|
597
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING PROFIT
|
|
|
|
2,082
|
|
2,293
|
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
|
|
|
29
|
|
7
|
|
|
Finance
expense
|
|
|
|
(203)
|
|
(205)
|
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
|
|
|
(2)
|
|
(1)
|
|
|
Profit/(loss)
on disposal of interests in associates
|
|
|
|
1
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE TAXATION
|
|
|
|
1,907
|
|
2,094
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
|
|
|
(276)
|
|
(323)
|
|
|
Tax rate %
|
|
|
|
14.5%
|
|
15.4%
|
|
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAXATION FROM CONTINUING OPERATIONS
|
|
|
|
1,631
|
|
1,771
|
|
|
|
|
|
|
|
|
|
|
|
Profit
after taxation from discontinued operations and other
gains
from
the demerger
|
|
|
|
-
|
|
396
|
|
|
PROFIT AFTER TAXATION FROM DISCONTINUED OPERATIONS
|
|
|
|
-
|
|
396
|
|
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAXATION FOR THE PERIOD
|
|
|
|
1,631
|
|
2,167
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests from
continuing
operations
|
|
|
|
141
|
|
275
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to shareholders from continuing
operations
|
|
|
|
1,490
|
|
1,496
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests from
discontinued
operations
|
|
|
|
-
|
|
90
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to shareholders from discontinued
operations
|
|
|
|
-
|
|
306
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,631
|
|
2,167
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
|
|
|
141
|
|
365
|
|
|
Profit
attributable to shareholders
|
|
|
|
1,490
|
|
1,802
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,631
|
|
2,167
|
|
|
|
|
|
|
|
|
|
|
|
EARNINGS PER SHARE FROM CONTINUING OPERATIONS
|
|
|
|
36.8p
|
|
37.3p
|
|
|
|
|
|
|
|
|
|
|
|
EARNINGS PER SHARE FROM DISCONTINUED OPERATIONS
|
|
|
|
-
|
|
7.6p
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL EARNINGS PER SHARE
|
|
|
|
36.8p
|
|
44.9p
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
earnings per share from continuing operations
|
|
|
|
36.5p
|
|
36.9p
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
earnings per share from discontinued operations
|
|
|
|
-
|
|
7.5p
|
|
|
|
|
|
|
|
|
|
|
|
Total
diluted earnings per share
|
|
|
|
36.5p
|
|
44.4p
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
The Q1 2022 comparative results
have been restated on a consistent basis from those previously
published to reflect the demerger of the Consumer Healthcare
business
(see page 33) and the impact of
Share Consolidation implemented on 18 July 2022 (see page
33).
|
|
Statement of comprehensive
income
|
|
|
|
|
|
Q1 2023
£m
|
|
Q1
2022(a)
£m
|
|
|
|
|
|
|
|
|
|
Total
profit for the period
|
|
|
|
1,631
|
|
2,167
|
|
|
|
|
|
|
|
|
|
Items that may be reclassified subsequently to continuing
operations income statement:
|
|
|
|
|
|
|
|
Exchange
movements on overseas net assets and net investment
hedges
|
|
|
|
87
|
|
(19)
|
|
Reclassification
of exchange movements on liquidation or disposal
of
overseas subsidiaries and associates
|
|
|
|
(3)
|
|
-
|
|
Fair
value movements on cash flow hedges
|
|
|
|
-
|
|
2
|
|
Reclassification
of cash flow hedges to income statement
|
|
|
|
1
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
85
|
|
(18)
|
|
|
|
|
|
|
|
|
|
Items that will not be reclassified to continuing operations income
statement:
|
|
|
|
|
|
|
|
Exchange
movements on overseas net assets of non-controlling
interests
|
|
|
|
(14)
|
|
3
|
|
Fair
value movements on equity investments
|
|
|
|
(168)
|
|
(543)
|
|
Tax on
fair value movements on equity investments
|
|
|
|
22
|
|
47
|
|
Remeasurement
gains/(losses) on defined benefit plans
|
|
|
|
350
|
|
313
|
|
Tax on
remeasurement losses/(gains) on defined benefit plans
|
|
|
|
(87)
|
|
(73)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
103
|
|
(253)
|
|
|
|
|
|
|
|
|
|
Other
comprehensive expense for the period from continuing
operations
|
|
|
|
188
|
|
(271)
|
|
|
|
|
|
|
|
|
|
Other
comprehensive income for the period from discontinued
operations
|
|
|
|
-
|
|
435
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the period
|
|
|
|
1,819
|
|
2,331
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the period attributable to:
|
|
|
|
|
|
|
|
Shareholders
|
|
|
|
1,692
|
|
1,962
|
|
Non-controlling
interests
|
|
|
|
127
|
|
369
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,819
|
|
2,331
|
|
|
|
|
|
|
|
|
|
(a)
|
The Q1 2022 comparative results
have been restated on a consistent basis from those previously
published to reflect the demerger of the Consumer Healthcare
business
(see page 33).
|
|
Balance sheet
|
|
|
31 March 2023
£m
|
|
31
December 2022
£m
|
|
ASSETS
|
|
|
|
|
Non-current assets
|
|
|
|
|
Property,
plant and equipment
|
8,758
|
|
8,933
|
|
Right
of use assets
|
656
|
|
687
|
|
Goodwill
|
6,857
|
|
7,046
|
|
Other
intangible assets
|
14,160
|
|
14,318
|
|
Investments
in associates and joint ventures
|
70
|
|
74
|
|
Other
investments
|
1,270
|
|
1,467
|
|
Deferred
tax assets
|
5,610
|
|
5,658
|
|
Other
non-current assets
|
1,496
|
|
1,194
|
|
|
|
|
|
|
Total non-current assets
|
38,877
|
|
39,377
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
Inventories
|
5,355
|
|
5,146
|
|
Current
tax recoverable
|
296
|
|
405
|
|
Trade
and other receivables
|
6,833
|
|
7,053
|
|
Derivative
financial instruments
|
125
|
|
190
|
|
Current
equity investments
|
4,020
|
|
4,087
|
|
Liquid
investments
|
65
|
|
67
|
|
Cash
and cash equivalents
|
2,890
|
|
3,723
|
|
Assets
held for sale
|
135
|
|
98
|
|
|
|
|
|
|
Total current assets
|
19,719
|
|
20,769
|
|
|
|
|
|
|
TOTAL ASSETS
|
58,596
|
|
60,146
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
Current liabilities
|
|
|
|
|
Short-term
borrowings
|
(4,261)
|
|
(3,952)
|
|
Contingent
consideration liabilities
|
(962)
|
|
(1,289)
|
|
Trade
and other payables
|
(14,268)
|
|
(16,263)
|
|
Derivative
financial instruments
|
(98)
|
|
(183)
|
|
Current
tax payable
|
(424)
|
|
(471)
|
|
Short-term
provisions
|
(683)
|
|
(652)
|
|
|
|
|
|
|
Total current liabilities
|
(20,696)
|
|
(22,810)
|
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
Long-term
borrowings
|
(16,644)
|
|
(17,035)
|
|
Corporation
tax payable
|
(123)
|
|
(127)
|
|
Deferred
tax liabilities
|
(290)
|
|
(289)
|
|
Pensions
and other post-employment benefits
|
(2,480)
|
|
(2,579)
|
|
Other
provisions
|
(537)
|
|
(532)
|
|
Contingent
consideration liabilities
|
(5,622)
|
|
(5,779)
|
|
Other
non-current liabilities
|
(892)
|
|
(899)
|
|
|
|
|
|
|
Total non-current liabilities
|
(26,588)
|
|
(27,240)
|
|
|
|
|
|
|
TOTAL LIABILITIES
|
(47,284)
|
|
(50,050)
|
|
|
|
|
|
|
NET ASSETS
|
11,312
|
|
10,096
|
|
|
|
|
|
|
EQUITY
|
|
|
|
|
Share
capital
|
1,348
|
|
1,347
|
|
Share
premium account
|
3,449
|
|
3,440
|
|
Retained
earnings
|
5,655
|
|
4,363
|
|
Other
reserves
|
1,368
|
|
1,448
|
|
|
|
|
|
|
Shareholders’ equity
|
11,820
|
|
10,598
|
|
|
|
|
|
|
Non-controlling
interests
|
(508)
|
|
(502)
|
|
|
|
|
|
|
TOTAL EQUITY
|
11,312
|
|
10,096
|
|
|
|
|
|
|
Statement of changes in
equity
|
|
|
Share
capital
£m
|
|
Share
premium
£m
|
|
Retained
earnings
£m
|
|
Other
reserves
£m
|
|
Share-
holder’s
equity
£m
|
|
Non-
controlling
interests
£m
|
|
Total
equity
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2023
|
1,347
|
|
3,440
|
|
4,363
|
|
1,448
|
|
10,598
|
|
(502)
|
|
10,096
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the period
|
|
|
|
|
1,490
|
|
|
|
1,490
|
|
141
|
|
1,631
|
|
Other
comprehensive
income/(expense)
for the period
|
|
|
|
|
336
|
|
(134)
|
|
202
|
|
(14)
|
|
188
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income/(expense)
for
the period
|
|
|
|
|
1,826
|
|
(134)
|
|
1,692
|
|
127
|
|
1,819
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions
to non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
(140)
|
|
(140)
|
|
Contributions
from non-controlling
interests
|
|
|
|
|
|
|
|
|
|
|
7
|
|
7
|
|
Dividends
to shareholders
|
|
|
|
|
(555)
|
|
|
|
(555)
|
|
|
|
(555)
|
|
Realised
after tax losses on disposal
or
liquidation of equity investments
|
|
|
|
|
(13)
|
|
13
|
|
|
|
|
|
-
|
|
Share
of associates and joint ventures
realised
profit/(loss) on disposal of equity investments
|
|
|
|
|
2
|
|
(2)
|
|
|
|
|
|
-
|
|
Shares
issued
|
1
|
|
7
|
|
|
|
|
|
8
|
|
|
|
8
|
|
Write-down
on shares held by ESOP
Trusts
|
|
|
|
|
(48)
|
|
48
|
|
|
|
|
|
-
|
|
Shares
acquired by ESOP Trusts
|
|
|
2
|
|
1
|
|
(3)
|
|
|
|
|
|
-
|
|
Share-based
incentive plans
|
|
|
|
|
79
|
|
|
|
79
|
|
|
|
79
|
|
Hedging
gain/loss after taxation
transferred
to non-financial assets
|
|
|
|
|
|
|
(2)
|
|
(2)
|
|
|
|
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 31 March 2023
|
1,348
|
|
3,449
|
|
5,655
|
|
1,368
|
|
11,820
|
|
(508)
|
|
11,312
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2022
|
1,347
|
|
3,301
|
|
7,944
|
|
2,463
|
|
15,055
|
|
6,287
|
|
21,342
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the period
|
|
|
|
|
1,802
|
|
|
|
1,802
|
|
365
|
|
2,167
|
|
Other
comprehensive
income/(expense)
for the period
|
|
|
|
|
507
|
|
(347)
|
|
160
|
|
4
|
|
164
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income/(expense)
for
the period
|
|
|
|
|
2,309
|
|
(347)
|
|
1,962
|
|
369
|
|
2,331
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions
to non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
(213)
|
|
(213)
|
|
Contributions
from non-controlling
interests
|
|
|
|
|
|
|
|
|
|
|
8
|
|
8
|
|
Dividends
to shareholders
|
|
|
|
|
(952)
|
|
|
|
(952)
|
|
|
|
(952)
|
|
Realised
after tax losses on disposal
of
equity investments
|
|
|
|
|
(10)
|
|
10
|
|
|
|
|
|
-
|
|
Shares
issued
|
|
|
17
|
|
|
|
|
|
17
|
|
|
|
17
|
|
Write-down
on shares held by ESOP
Trusts
|
|
|
|
|
(457)
|
|
457
|
|
|
|
|
|
-
|
|
Shares
acquired by ESOP Trusts
|
|
|
118
|
|
704
|
|
(822)
|
|
|
|
|
|
-
|
|
Share-based
incentive plans
|
|
|
|
|
99
|
|
|
|
99
|
|
|
|
99
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 31
March 2022
|
1,347
|
|
3,436
|
|
9,637
|
|
1,761
|
|
16,181
|
|
6,451
|
|
22,632
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flow statement – three
months ended 31 March 2023
|
|
|
Q1 2023
£m
|
|
Q1
2022(a)
£m
|
|
Profit after tax from continuing operations
|
1,631
|
|
1,771
|
|
Tax on
profits
|
276
|
|
323
|
|
Share
of after tax loss/(profit) of associates and joint
ventures
|
2
|
|
1
|
|
(Profit)/loss
on disposal of interest in associates and joint
ventures
|
(1)
|
|
-
|
|
Net
finance expense
|
174
|
|
198
|
|
Depreciation,
amortisation and other adjusting items
|
640
|
|
418
|
|
Decrease/(Increase)
in working capital
|
(840)
|
|
(479)
|
|
Contingent
consideration paid
|
(290)
|
|
(185)
|
|
Increase/(decrease)
in other net liabilities (excluding contingent consideration
paid)
|
(1,305)
|
|
305
|
|
|
|
|
|
|
Cash generated from operations attributable to continuing
operations
|
287
|
|
2,352
|
|
Taxation
paid
|
(234)
|
|
(146)
|
|
|
|
|
|
|
Net cash inflow/(outflow) from continuing operating
activities
|
53
|
|
2,206
|
|
Cash
generated from operations attributable to discontinued
operations
|
-
|
|
403
|
|
Taxation
paid from discontinued operations
|
-
|
|
(67)
|
|
Net operating cash flows attributable to discontinued
operations
|
-
|
|
336
|
|
|
|
|
|
|
Total net cash inflows/(outflows) from operating
activities
|
53
|
|
2,542
|
|
|
|
|
|
|
Cash flow from investing activities
|
|
|
|
|
Purchase
of property, plant and equipment
|
(233)
|
|
(193)
|
|
Proceeds
from sale of property, plant and equipment
|
7
|
|
6
|
|
Purchase
of intangible assets
|
(296)
|
|
(377)
|
|
Proceeds
from sale of intangible assets
|
4
|
|
5
|
|
Purchase
of equity investments
|
(56)
|
|
(45)
|
|
Proceeds
from sale of equity investments
|
10
|
|
-
|
|
Contingent
consideration paid
|
(1)
|
|
(26)
|
|
Disposal
of businesses
|
(6)
|
|
1
|
|
Interest
received
|
29
|
|
8
|
|
Proceeds
from disposal of associates and joint ventures
|
1
|
|
-
|
|
Dividend
and distributions from investments
|
132
|
|
-
|
|
Dividends
from associates and joint ventures
|
1
|
|
-
|
|
|
|
|
|
|
Net cash inflow/(outflow) from continuing investing
activities
|
(408)
|
|
(621)
|
|
Net
investing cash flows attributable to discontinued
operations
|
-
|
|
(2,972)
|
|
|
|
|
|
|
Total net cash inflow/(outflow) from investing
activities
|
(408)
|
|
(3,593)
|
|
|
|
|
|
|
Cash flow from financing activities
|
|
|
|
|
Issue
of share capital
|
8
|
|
17
|
|
Decrease
in long-term loans
|
(144)
|
|
-
|
|
Net
increase/(repayment) of short-term loans
|
552
|
|
(249)
|
|
Repayment
of lease liabilities
|
(47)
|
|
(51)
|
|
Interest
paid
|
(120)
|
|
(82)
|
|
Dividends
paid to shareholders
|
(555)
|
|
(952)
|
|
Shares
acquired by ESOP Trusts
|
(2)
|
|
(7)
|
|
Distribution
to non-controlling interests
|
(140)
|
|
(78)
|
|
Contributions
from non-controlling interests
|
7
|
|
8
|
|
Other
financing items
|
123
|
|
91
|
|
|
|
|
|
|
Net cash inflow/(outflow) from continuing financing
activities
|
(318)
|
|
(1,303)
|
|
Net
financing cash flows attributable to discontinued
operations
|
-
|
|
9,276
|
|
|
|
|
|
|
Total net cash inflow/(outflow) from financing
activities
|
(318)
|
|
7,973
|
|
|
|
|
|
|
Increase/(decrease) in cash and bank overdrafts in the
period
|
(673)
|
|
6,922
|
|
|
|
|
|
|
Cash
and bank overdrafts at beginning of the period
|
3,425
|
|
3,817
|
|
Exchange
adjustments
|
(31)
|
|
12
|
|
Increase/(decrease)
in cash and bank overdrafts
|
(673)
|
|
6,922
|
|
|
|
|
|
|
Cash and bank overdrafts at end of the period
|
2,721
|
|
10,751
|
|
|
|
|
|
|
Cash
and bank overdrafts at end of the period comprise:
|
|
|
|
|
Cash
and cash equivalents
|
2,890
|
|
10,967
|
|
Overdrafts
|
(169)
|
|
(216)
|
|
|
|
|
|
|
|
2,721
|
|
10,751
|
|
|
|
|
|
|
(a)
|
The Q1 2022 comparative results
have been restated on a consistent basis from those previously
published to reflect the demerger of the Consumer Healthcare
business
(see page 33).
|
|
Vaccines turnover – three
months ended 31 March 2023
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shingles
|
833
|
|
19
|
|
11
|
|
508
|
|
4
|
|
(5)
|
|
214
|
|
34
|
|
27
|
|
111
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shingrix
|
833
|
|
19
|
|
11
|
|
508
|
|
4
|
|
(5)
|
|
214
|
|
34
|
|
27
|
|
111
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis
|
280
|
|
32
|
|
25
|
|
119
|
|
20
|
|
10
|
|
115
|
|
39
|
|
33
|
|
46
|
|
53
|
|
50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bexsero
|
218
|
|
34
|
|
26
|
|
74
|
|
12
|
|
3
|
|
110
|
|
39
|
|
34
|
|
34
|
|
89
|
|
78
|
|
Menveo
|
59
|
|
40
|
|
31
|
|
45
|
|
36
|
|
24
|
|
4
|
|
33
|
|
-
|
|
10
|
|
67
|
|
83
|
|
Other
|
3
|
|
(57)
|
|
(57)
|
|
-
|
|
-
|
|
-
|
|
1
|
|
-
|
|
-
|
|
2
|
|
(67)
|
|
(67)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Influenza
|
12
|
|
(33)
|
|
(28)
|
|
1
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
11
|
|
(35)
|
|
(29)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fluarix, FluLaval
|
12
|
|
(33)
|
|
(28)
|
|
1
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
11
|
|
(35)
|
|
(29)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established Vaccines
|
815
|
|
10
|
|
4
|
|
353
|
|
17
|
|
7
|
|
193
|
|
16
|
|
12
|
|
269
|
|
(1)
|
|
(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Infanrix, Pediarix
|
177
|
|
1
|
|
(5)
|
|
108
|
|
(4)
|
|
(12)
|
|
33
|
|
14
|
|
14
|
|
36
|
|
6
|
|
-
|
|
Boostrix
|
139
|
|
10
|
|
3
|
|
92
|
|
31
|
|
20
|
|
31
|
|
(6)
|
|
(9)
|
|
16
|
|
(30)
|
|
(30)
|
|
Hepatitis
|
170
|
|
39
|
|
31
|
|
98
|
|
26
|
|
15
|
|
46
|
|
59
|
|
52
|
|
26
|
|
73
|
|
73
|
|
Rotarix
|
138
|
|
18
|
|
14
|
|
47
|
|
34
|
|
23
|
|
33
|
|
3
|
|
-
|
|
58
|
|
16
|
|
16
|
|
Synflorix
|
62
|
|
(23)
|
|
(26)
|
|
-
|
|
-
|
|
-
|
|
8
|
|
33
|
|
33
|
|
54
|
|
(28)
|
|
(31)
|
|
Priorix, Priorix Tetra,
Varilrix
|
53
|
|
13
|
|
9
|
|
2
|
|
-
|
|
-
|
|
33
|
|
18
|
|
7
|
|
18
|
|
(5)
|
|
-
|
|
Cervarix
|
27
|
|
(7)
|
|
(7)
|
|
-
|
|
-
|
|
-
|
|
9
|
|
>100
|
|
>100
|
|
18
|
|
(28)
|
|
(24)
|
|
Other
|
49
|
|
11
|
|
-
|
|
6
|
|
(14)
|
|
(43)
|
|
-
|
|
(100)
|
|
(80)
|
|
43
|
|
34
|
|
22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines excluding
COVID-19 solutions
|
1,940
|
|
16
|
|
9
|
|
981
|
|
10
|
|
1
|
|
522
|
|
28
|
|
22
|
|
437
|
|
19
|
|
17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pandemic vaccines
|
101
|
|
100
|
|
100
|
|
-
|
|
-
|
|
-
|
|
101
|
|
100
|
|
100
|
|
-
|
|
-
|
|
-
|
|
Pandemic
adjuvant
|
101
|
|
100
|
|
100
|
|
-
|
|
-
|
|
-
|
|
101
|
|
100
|
|
100
|
|
-
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines
|
2,041
|
|
22
|
|
15
|
|
981
|
|
10
|
|
1
|
|
623
|
|
52
|
|
45
|
|
437
|
|
19
|
|
17
|
|
Specialty Medicines turnover –
three months ended 31 March 2023
|
||||||||||||||||||||||||
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,468
|
|
24
|
|
15
|
|
917
|
|
32
|
|
20
|
|
346
|
|
16
|
|
11
|
|
205
|
|
11
|
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dolutegravir
products
|
1,277
|
|
16
|
|
8
|
|
760
|
|
19
|
|
8
|
|
319
|
|
11
|
|
7
|
|
198
|
|
14
|
|
7
|
|
|
Tivicay
|
357
|
|
12
|
|
3
|
|
185
|
|
16
|
|
6
|
|
66
|
|
2
|
|
(2)
|
|
106
|
|
12
|
|
-
|
|
|
Triumeq
|
374
|
|
(5)
|
|
(11)
|
|
249
|
|
2
|
|
(7)
|
|
75
|
|
(20)
|
|
(23)
|
|
50
|
|
(6)
|
|
(8)
|
|
|
Juluca
|
150
|
|
13
|
|
5
|
|
111
|
|
12
|
|
3
|
|
35
|
|
17
|
|
10
|
|
4
|
|
-
|
|
-
|
|
|
Dovato
|
396
|
|
54
|
|
44
|
|
215
|
|
57
|
|
43
|
|
143
|
|
46
|
|
40
|
|
38
|
|
73
|
|
73
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
25
|
|
56
|
|
44
|
|
23
|
|
53
|
|
40
|
|
2
|
|
100
|
|
100
|
|
-
|
|
-
|
|
-
|
|
|
Cabenuva
|
127
|
|
>100
|
|
>100
|
|
103
|
|
>100
|
|
>100
|
|
20
|
|
>100
|
|
>100
|
|
4
|
|
>100
|
|
>100
|
|
|
Apretude
|
24
|
|
>100
|
|
>100
|
|
24
|
|
>100
|
|
>100
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
|
Other
|
15
|
|
(35)
|
|
(35)
|
|
7
|
|
-
|
|
(14)
|
|
5
|
|
-
|
|
(20)
|
|
3
|
|
(73)
|
|
(55)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immunology/
Respiratory and Other
|
601
|
|
16
|
|
9
|
|
393
|
|
13
|
|
4
|
|
108
|
|
29
|
|
23
|
|
100
|
|
12
|
|
15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Benlysta
|
253
|
|
18
|
|
9
|
|
204
|
|
20
|
|
10
|
|
23
|
|
21
|
|
16
|
|
26
|
|
-
|
|
-
|
|
|
Nucala
|
347
|
|
18
|
|
11
|
|
189
|
|
7
|
|
(2)
|
|
89
|
|
37
|
|
31
|
|
69
|
|
30
|
|
32
|
|
|
Other
|
1
|
|
(90)
|
|
(80)
|
|
-
|
|
-
|
|
-
|
|
(4)
|
|
-
|
|
-
|
|
5
|
|
(50)
|
|
(40)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
136
|
|
7
|
|
2
|
|
55
|
|
(20)
|
|
(28)
|
|
72
|
|
33
|
|
28
|
|
9
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Zejula
|
114
|
|
16
|
|
10
|
|
50
|
|
(2)
|
|
(10)
|
|
55
|
|
28
|
|
21
|
|
9
|
|
>100
|
|
>100
|
|
|
Blenrep
|
11
|
|
(56)
|
|
(56)
|
|
-
|
|
(100)
|
|
(100)
|
|
11
|
|
22
|
|
22
|
|
-
|
|
-
|
|
-
|
|
|
Jemperli
|
11
|
|
>100
|
|
>100
|
|
5
|
|
>100
|
|
>100
|
|
5
|
|
>100
|
|
>100
|
|
1
|
|
>100
|
|
>100
|
|
|
Other
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
1
|
|
-
|
|
-
|
|
(1)
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Specialty Medicines
excluding COVID-19
solutions
|
2,205
|
|
21
|
|
13
|
|
1,365
|
|
23
|
|
12
|
|
526
|
|
20
|
|
15
|
|
314
|
|
13
|
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pandemic
|
31
|
|
(98)
|
|
(98)
|
|
-
|
|
(100)
|
|
(100)
|
|
-
|
|
(100)
|
|
(100)
|
|
31
|
|
(86)
|
|
(87)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Xevudy
|
31
|
|
(98)
|
|
(98)
|
|
-
|
|
(100)
|
|
(100)
|
|
-
|
|
(100)
|
|
(100)
|
|
31
|
|
(86)
|
|
(87)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Specialty Medicines
|
2,236
|
|
(29)
|
|
(33)
|
|
1,365
|
|
(28)
|
|
(34)
|
|
526
|
|
(30)
|
|
(33)
|
|
345
|
|
(32)
|
|
(34)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General Medicines turnover –
three months ended 31 March 2023
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
1,767
|
|
15
|
|
10
|
|
832
|
|
15
|
|
5
|
|
372
|
|
12
|
|
8
|
|
563
|
|
17
|
|
18
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Arnuity Ellipta
|
8
|
|
(38)
|
|
(38)
|
|
6
|
|
(45)
|
|
(45)
|
|
-
|
|
-
|
|
-
|
|
2
|
|
-
|
|
-
|
|
Anoro Ellipta
|
120
|
|
22
|
|
16
|
|
51
|
|
24
|
|
15
|
|
46
|
|
21
|
|
18
|
|
23
|
|
21
|
|
16
|
|
Avamys/Veramyst
|
124
|
|
32
|
|
31
|
|
-
|
|
-
|
|
-
|
|
18
|
|
12
|
|
6
|
|
106
|
|
36
|
|
36
|
|
Flixotide/Flovent
|
157
|
|
24
|
|
16
|
|
106
|
|
25
|
|
14
|
|
21
|
|
17
|
|
11
|
|
30
|
|
25
|
|
25
|
|
Incruse Ellipta
|
35
|
|
(30)
|
|
(34)
|
|
13
|
|
(50)
|
|
(54)
|
|
16
|
|
-
|
|
(6)
|
|
6
|
|
(25)
|
|
(25)
|
|
Relvar/Breo Ellipta
|
274
|
|
-
|
|
(5)
|
|
100
|
|
(17)
|
|
(23)
|
|
98
|
|
18
|
|
13
|
|
76
|
|
6
|
|
6
|
|
Seretide/Advair
|
339
|
|
12
|
|
8
|
|
120
|
|
43
|
|
30
|
|
71
|
|
(3)
|
|
(7)
|
|
148
|
|
2
|
|
2
|
|
Trelegy Ellipta
|
465
|
|
37
|
|
28
|
|
327
|
|
37
|
|
26
|
|
67
|
|
26
|
|
23
|
|
71
|
|
45
|
|
47
|
|
Ventolin
|
205
|
|
2
|
|
(3)
|
|
108
|
|
(8)
|
|
(15)
|
|
28
|
|
(7)
|
|
(10)
|
|
69
|
|
28
|
|
28
|
|
Other
Respiratory
|
40
|
|
14
|
|
17
|
|
1
|
|
-
|
|
-
|
|
7
|
|
17
|
|
17
|
|
32
|
|
10
|
|
17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other General Medicines
|
907
|
|
7
|
|
7
|
|
92
|
|
3
|
|
(6)
|
|
183
|
|
8
|
|
4
|
|
632
|
|
7
|
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
97
|
|
5
|
|
8
|
|
-
|
|
-
|
|
-
|
|
28
|
|
4
|
|
-
|
|
69
|
|
6
|
|
11
|
|
Augmentin
|
177
|
|
37
|
|
38
|
|
-
|
|
-
|
|
-
|
|
56
|
|
56
|
|
50
|
|
121
|
|
30
|
|
33
|
|
Avodart
|
92
|
|
14
|
|
9
|
|
-
|
|
-
|
|
-
|
|
29
|
|
7
|
|
4
|
|
63
|
|
17
|
|
11
|
|
Lamictal
|
129
|
|
8
|
|
2
|
|
66
|
|
12
|
|
2
|
|
28
|
|
8
|
|
8
|
|
35
|
|
-
|
|
(3)
|
|
Other
|
412
|
|
(4)
|
|
-
|
|
26
|
|
(13)
|
|
(20)
|
|
42
|
|
(22)
|
|
(28)
|
|
344
|
|
-
|
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General Medicines
|
2,674
|
|
12
|
|
9
|
|
924
|
|
14
|
|
4
|
|
555
|
|
10
|
|
6
|
|
1,195
|
|
11
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial Operations turnover
– three months ended 31 March 2023
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
31 March 2023
|
6,951
|
|
(3)
|
|
(8)
|
|
3,270
|
|
(9)
|
|
(17)
|
|
1,704
|
|
3
|
|
(2)
|
|
1,977
|
|
2
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial Operations turnover
excluding COVID-19 solutions
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
31 March 2023
|
6,819
|
|
16
|
|
10
|
|
3,270
|
|
16
|
|
6
|
|
1,603
|
|
19
|
|
14
|
|
1,946
|
|
13
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment
information
|
|
Operating
segments are reported based on the financial information provided
to the Chief Executive Officer and the responsibilities of the GSK
Leadership Team (GLT). GSK reports results under two segments:
Commercial Operations and Total R&D. Members of the GLT are
responsible for each segment. The Consumer Healthcare segment is
presented as discontinued operations in Q1 2022 for comparative
purposes and therefore no segment information is
presented.
R&D
investment is essential for the sustainability of the business.
However, for segment reporting the Commercial operating profits
exclude allocations of globally funded R&D.
The
Total R&D segment is the responsibility of the Chief Scientific
Officer and is reported as a separate segment. The operating costs
of this segment includes R&D activities across Specialty
Medicines, including HIV and Vaccines. It includes R&D and some
SG&A costs relating to regulatory and other
functions.
The
Group’s management reporting process allocates intra-Group
profit on a product sale to the market in which that sale is
recorded, and the profit analyses below have been presented on that
basis.
|
|
Turnover by
segment
|
|||||||
|
|
Q1 2023
£m
|
|
Q1
2022(a)
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations (total turnover)
|
6,951
|
|
7,190
|
|
(3)
|
|
(8)
|
|
|
|
|
|
|
|
|
|
|
Operating profit by
segment
|
|||||||
|
|
Q1 2023
£m
|
|
Q1
2022
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
3,375
|
|
3,117
|
|
8
|
|
1
|
|
Research
and Development
|
(1,232)
|
|
(1,095)
|
|
13
|
|
6
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
2,143
|
|
2,022
|
|
6
|
|
(2)
|
|
Corporate
and other unallocated costs
|
(51)
|
|
(79)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
2,092
|
|
1,943
|
|
8
|
|
-
|
|
Adjusting
items
|
(10)
|
|
350
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
2,082
|
|
2,293
|
|
(9)
|
|
(15)
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
29
|
|
7
|
|
|
|
|
|
Finance
costs
|
(203)
|
|
(205)
|
|
|
|
|
|
Share
of after tax profit/(loss) of associates
and
joint ventures
|
(2)
|
|
(1)
|
|
|
|
|
|
Profit
on disposal of associates and joint ventures
|
1
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation from continuing operations
|
1,907
|
|
2,094
|
|
(9)
|
|
(15)
|
|
|
|
|
|
|
|
|
|
|
(a)
|
The Q1 2022 comparative results
have been restated on a consistent basis from those previously
published to reflect the demerger of the Consumer Healthcare
business
(see page 33).
|
|
Legal matters
|
|
The
Group is involved in significant legal and administrative
proceedings, principally product liability, intellectual property,
tax, anti-trust, consumer fraud and governmental investigations,
which are more fully described in the ‘Legal
Proceedings’ note in the Annual Report 2022. At 31 March
2023, the Group’s aggregate provision for legal and other
disputes (not including tax matters described on page 9) was
£0.3 billion (31 December 2022: £0.2
billion).
The
Group may become involved in significant legal proceedings in
respect of which it is not possible to meaningfully assess whether
the outcome will result in a probable outflow, or to quantify or
reliably estimate the liability, if any, that could result from
ultimate resolution of the proceedings. In these cases, the Group
would provide appropriate disclosures about such cases, but no
provision would be made.
The
ultimate liability for legal claims may vary from the amounts
provided and is dependent upon the outcome of litigation
proceedings, investigations and possible settlement negotiations.
The Group’s position could change over time, and, therefore,
there can be no assurance that any losses that result from the
outcome of any legal proceedings will not exceed by a material
amount the amount of the provisions reported in the Group’s
financial accounts.
Significant
legal developments since the date of the Annual Report
2022:
Intellectual
Property
Coreg
On 29
March 2023, the US Solicitor General filed a brief with the US
Supreme Court expressing the view that Teva’s petition for
certiorari should be granted. GSK filed a reply to the US Solicitor
General’s brief on 11 April 2023, again arguing that
Teva’s petition for certiorari be denied.
Tivicay
In
September 2021, ViiV Healthcare received a paragraph IV letter from
Lupin Ltd. (Lupin) relating to the Tivicay 5mg dosage for oral suspension,
challenging only the crystal form patent. On 2 November 2021, ViiV
Healthcare filed suit against Lupin in the US District Court for
the District of Delaware. In March 2023, the parties reached a
settlement, thereby concluding the matter.
Juluca
On 12
June 2020, ViiV Healthcare received a paragraph IV letter from
Cipla Ltd. (Cipla) relating to Juluca. On 22 July 2020, ViiV
Healthcare filed suit against Cipla in the US District Court for
the District of Delaware. In March 2023, the parties reached a
settlement, thereby concluding the matter.
Product
Liability
Zantac
On 23
March 2023, the court presiding over the California Zantac litigation cases issued a Sargon
ruling in the first case scheduled for trial (Goetz). The court found that the
plaintiff’s experts’ causation opinions are admissible
and can be presented to a jury. This ruling does not mean that the
Court agrees with plaintiff’s experts’ scientific
conclusions as plaintiff must still prove his case at trial. The
ruling applies only to the Goetz case and does not affect any
other state cases or the December 2022 MDL Daubert ruling. The
Goetz trial is scheduled to
begin on 24 July 2023.
Two
cases have been set for trial in 2024 in the Cook County, Illinois
proceedings.
GSK
will continue to defend itself vigorously against all
claims.
Sales and marketing and
regulation
US electronic health records subpoena
On 19
March 2023, the Group received a subpoena from the United States
Attorney’s Office for the Western District of Virginia, which
is working with the United States Department of Justice Civil
Division, seeking documents relating to the Group’s
electronic health record programmes. The Group is cooperating with
this enquiry.
Commercial and
corporate
Zejula Royalty
Dispute
Trial
was held the week of 6 March 2023 and judgment was entered against
the Group on 5 April 2023. The Court upheld AstraZeneca’s
interpretation that all current uses of Zejula generate royalty-bearing sales
under the wording of the two license agreements. Accordingly, GSK
will owe back royalties to AstraZeneca in an amount to be
determined in a separate phase of the proceedings. The Group will
also be responsible for paying on this same basis going forward.
The Group is considering an appeal.
|
|
Returns
to shareholders
|
|
Quarterly dividends
The
Board has declared a first interim dividend for Q1 2023 of 14p per
share (Q1 2022: 17.50p(1) per share
retrospectively adjusted for the Share Consolidation).
Dividends
remain an essential component of total shareholder return and GSK
recognises the importance of dividends to shareholders. On 23 June
2021, at the GSK Investor Update, GSK set out that from 2022 a
progressive dividend policy will be implemented guided by a 40 to
60 percent pay-out ratio through the investment cycle. The dividend
policy, the total expected cash distribution, and the respective
dividend pay-out ratios for GSK remain unchanged. GSK expects to
declare a dividend of 56.5p per share for 2023.
Payment of dividends
The
equivalent interim dividend receivable by ADR holders will be
calculated based on the exchange rate on 11 July 2023. An annual
fee of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by
the Depositary. The ex-dividend date will be 18 May 2023, with a
record date of 19 May 2023 and a payment date of 13 July
2023.
|
|
|
Paid/
Payable
|
|
Pence
per
share/
pre
share
consolidation
|
|
Pence
per
share/
post
share
consolidation
|
|
£m
|
|
|
|
|
|
|
|
|
|
|
2023
|
|
|
|
|
|
|
|
|
First
interim
|
13 July
2023
|
|
-
|
|
14
|
|
567
|
|
|
|
|
|
|
|
|
|
|
2022
|
|
|
|
|
|
|
|
|
First
interim
|
1 July
2022
|
|
14
|
|
17.50
|
|
704
|
|
Second
interim
|
6
October 2022
|
|
13
|
|
16.25
|
|
654
|
|
Third
interim
|
12
January 2023
|
|
11
|
|
13.75
|
|
555
|
|
Fourth
interim
|
13
April 2023
|
|
11
|
|
13.75
|
|
557
|
|
|
|
|
|
|
|
|
|
|
|
|
|
49
|
|
61.25
|
|
2,470
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Adjusted
for the Share Consolidation on 18 July 2022. For details of the
Share Consolidation see page 33.
|
|
Weighted average number of
shares
|
|||||
|
|
|
|
Q1 2023
millions
|
|
Q1
2022
millions(a)
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – basic
|
|
|
4,044
|
|
4,016
|
|
Dilutive
effect of share options and share awards
|
|
|
41
|
|
50
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – diluted
|
|
|
4,085
|
|
4,066
|
|
|
|
|
|
|
|
|
(a)
|
See page 33 for details of the
Share Consolidation.
|
|
At 31
March 2023, 4,052 million shares (Q1 2022: 4,024 million) were in
free issue (excluding Treasury shares and shares held by the ESOP
Trusts). No Treasury shares have been repurchased since 2014. The
Company issued 0.7 million shares under employee share schemes in
the period for proceeds of £8 million (Q1 2022: £17
million).
|
|
At 31
March 2023, the ESOP Trusts held 42.7 million GSK shares against
the future exercise of share options and share awards. The carrying
value of £293 million has been deducted from other reserves.
The market value of these shares was £615
million.
At 31
March 2023, the Company held 217 million Treasury shares at a cost
of £3,796 million which has been deducted from retained
earnings.
|
|
Additional
information
|
|
Disposal group and discontinued operations accounting
policy
Disposal
groups are classified as held for distribution if their carrying
amount will be recovered principally through a distribution to
shareholders rather than through continuing use, they are available
for distribution in their present condition and the distribution is
considered highly probable. They are measured at the lower of their
carrying amount and fair value less costs to
distribute.
Non-current
assets included as part of a disposal group are not depreciated or
amortised while they are classified as held for distribution. The
assets and liabilities of a disposal group classified as held for
distribution are presented separately from the other assets and
liabilities in the balance sheet.
A
discontinued operation is a component of the entity that has been
disposed of or distributed or is classified as held for
distribution and that represents a separate major line of business.
The results of discontinued operations are presented separately in
the statement of profit or loss and comparatives are restated on a
consistent basis.
The Q1 2022 comparative figures have been restated on a consistent
basis in the first quarter 2023 from those previously published to
reflect the demerger of the Consumer Healthcare business in July
2022.
Accounting policies and basis of preparation
This
unaudited Results Announcement contains condensed financial
information for the three months ended
31 March 2023 and should be read in conjunction with the Annual
Report 2022, which was prepared in accordance with
United
Kingdom adopted International Financial Reporting Standards.
This Results Announcement has been prepared applying consistent
accounting policies to those applied by the Group in the Annual
Report 2022.
The
Group has not identified any changes to its key sources of
accounting judgements or estimations of uncertainty compared with
those disclosed in the Annual Report 2022.
|
|
This
Results Announcement does not constitute statutory accounts of the
Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The full Group accounts for 2022 were published
in the Annual Report 2022, which has been delivered to the
Registrar of Companies and on which the report of the independent
auditor was unqualified and did not contain a statement under
section 498 of the Companies Act 2006.
|
|
Exchange rates
|
|
GSK
operates in many countries and earns revenues and incurs costs in
many currencies. The results of the Group, as reported in Sterling,
are affected by movements in exchange rates between Sterling and
other currencies. Average exchange rates, as modified by specific
transaction rates for large transactions, prevailing during the
period, are used to translate the results and cash flows of
overseas subsidiaries, associates and joint ventures into Sterling.
Period-end rates are used to translate the net assets of those
entities. The currencies which most influenced these translations
and the relevant exchange rates were:
|
|
|
|
|
Q1 2023
|
|
Q1
2022
|
|
2022
|
||
|
|
|
|
|
|
|
|
|
||
|
Average
rates:
|
|
|
|
|
|
|
|
||
|
|
|
US$/£
|
|
|
1.22
|
|
1.34
|
|
1.24
|
|
|
|
Euro/£
|
|
|
1.14
|
|
1.19
|
|
1.17
|
|
|
|
Yen/£
|
|
|
162
|
|
156
|
|
161
|
|
|
|
|
|
|
|
|
|
||
|
Period-end
rates:
|
|
|
|
|
|
|
|
||
|
|
|
US$/£
|
|
|
1.24
|
|
1.31
|
|
1.20
|
|
|
|
Euro/£
|
|
|
1.14
|
|
1.18
|
|
1.13
|
|
|
|
Yen/£
|
|
|
165
|
|
160
|
|
159
|
|
Net assets
|
|
The
book value of net assets increased by £1,216 million from
£10,096 million at 31 December 2022 to £11,312 million at
31 March 2023. This primarily reflected contribution from Total
comprehensive income for the period partly offset by dividend paid
to shareholders.
At 31
March 2023, the net deficit on the Group’s pension plans was
£966 million compared with £1,355 million at 31 December
2022. This decrease in the net deficit is primarily driven by
higher asset values in the UK.
The
estimated present value of the potential redemption amount of the
Pfizer put option related to ViiV Healthcare, recorded in Other
payables in Current liabilities, was £988 million (31 December
2022: £1,093 million).
Contingent
consideration amounted to £6,584 million at 31 March 2023 (31
December 2022: £7,068 million), of which £5,539 million
(31 December 2022: £5,890 million) represented the estimated
present value of amounts payable to Shionogi relating to ViiV
Healthcare, £587 million (31 December 2022: £673 million)
represented the estimated present value of contingent consideration
payable to Novartis related to the Vaccines acquisition and
£455 million (31 December 2022: £501 million) represented
the estimated present value of contingent consideration payable to
Affinivax.
Of the
contingent consideration payable (on a post-tax basis) to Shionogi
at 31 March 2023, £925 million (31 December 2022: £940
million) is expected to be paid within one year.
|
|
Movements in contingent consideration are as follows:
|
|
Q1
2023
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,890
|
|
7,068
|
|
Remeasurement
through income statement and other movements
|
(64)
|
|
(193)
|
|
Cash
payments: operating cash flows
|
(287)
|
|
(290)
|
|
Cash
payments: investing activities
|
-
|
|
(1)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
5,539
|
|
6,584
|
|
|
|
|
|
|
Q1 2022
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,559
|
|
6,076
|
|
Remeasurement
through income statement and other movements
|
256
|
|
304
|
|
Cash
payments: operating cash flows
|
(183)
|
|
(185)
|
|
Cash
payments: investing activities
|
(25)
|
|
(26)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
5,607
|
|
6,169
|
|
|
|
|
|
|
Contingent
liabilities
|
|
There
were contingent liabilities at 31 March 2023 in respect of
guarantees and indemnities entered into as part of the ordinary
course of the Group’s business. No material losses are
expected to arise from such contingent liabilities. Provision is
made for the outcome of legal and tax disputes where it is both
probable that the Group will suffer an outflow of funds and it is
possible to make a reliable estimate of that outflow. Descriptions
of the significant legal disputes to which the Group is a party are
set out on page 29 and on pages 265 to 267 of the 2022 Annual
Report.
|
|
Business
acquisitions
|
|
On 18 April 2023, GSK announced it had reached agreement to acquire
late-stage biopharmaceutical company Bellus Health for US$14.75 per
share of common stock in cash representing an approximate total
equity value of US $2.0 billion (£1.6 billion). The
acquisition provides GSK access to camlipixant, a potential
best-in-class and highly selective P2X3 antagonist currently in
phase III development for the first-line treatment of adult
patients with refractory chronic cough (RCC). Under the terms of
the agreement, the acquisition will be effected through a Plan of
Arrangement pursuant to the Canada Business Corporations Act in
which the shares of Bellus outstanding will be acquired by GSK in
consideration of US$14.75 per share in cash. Subject to customary
conditions, including court approval, the approval of the
acquisition by at least 66.67% of the votes cast at a meeting of
Bellus' shareholders and a majority of the votes cast by
non-interested shareholders at such meeting, and approval by the
appropriate regulatory agencies, the transaction is expected to
close in the third quarter of 2023 or earlier.
|
|
Discontinued
operations
|
|
Consumer
Healthcare was presented as a discontinued operation from Q2 2022.
The demerger of Consumer Healthcare was completed on 18 July 2022.
Financial information relating to the operations of Consumer
Healthcare for the period ended 31 March 2022 is set out below.
In Q1 2023, the Q1 2022 comparative
figures are restated on a consistent basis from the previously
published figures. The Group Income Statement and Group Cash
Flow Statement distinguish discontinued operations from continuing
operations.
|
|
Total
Results
|
|
|
Q1
2022
£m
|
|
|
|
|
|
|
Turnover
|
|
|
2,590
|
|
Other
income/(expense)
|
|
|
(2,086)
|
|
|
|
|
|
|
Profit
before tax
|
|
|
504
|
|
Taxation
|
|
|
(108)
|
|
Tax rate%
|
|
|
21.4%
|
|
|
|
|
|
|
Profit/(loss) after
taxation from discontinued operations: Consumer
Healthcare
|
|
|
396
|
|
|
|
|
|
|
Other
gains/(losses) from the demerger
|
|
|
-
|
|
Remeasurement of
discontinued operations distributed to shareholders on
demerger
|
|
|
-
|
|
|
|
|
|
|
Profit
after taxation from discontinued operations
|
|
|
396
|
|
|
|
|
|
|
Non-controlling
interest in discontinued operations
|
|
|
90
|
|
Earnings
attributable to shareholders from discontinued
operations
|
|
|
306
|
|
|
|
|
|
|
Earnings per share
from discontinued operations
|
|
|
7.6p
|
|
|
|
|
|
|
Share
Consolidation
Following
completion of the Consumer Healthcare business demerger on 18 July
2022, GSK plc Ordinary shares were consolidated to maintain share
price comparability before and after demerger. The consolidation
was approved by GSK shareholders at a General Meeting held on 6
July 2022. Shareholders received 4 new Ordinary shares with a
nominal value of 31¼ pence each for every 5 existing Ordinary
shares which had a nominal value of 25 pence each. Earnings per
share, diluted earnings per share, adjusted earnings per share and
dividends per share were retrospectively adjusted to reflect the
Share Consolidation in all the periods presented.
|
|
Related party
transactions
Details
of GSK’s related party transactions are disclosed on page 236
of our 2022 Annual Report.
|
|
Reconciliation of cash flow to
movements in net debt
|
|
|
Q1 2023
£m
|
|
Q1
2022
£m
|
|
|
|
|
|
|
Total
Net debt at beginning of the period
|
(17,197)
|
|
(19,838)
|
|
|
|
|
|
|
Increase/(decrease)
in cash and bank overdrafts
|
(673)
|
|
282
|
|
Net
decrease/(increase) in short-term loans
|
(552)
|
|
249
|
|
Net
decrease/(increase) in long-term loans
|
144
|
|
-
|
|
Repayment
of lease liabilities
|
47
|
|
51
|
|
Exchange
adjustments
|
322
|
|
(356)
|
|
Other
non-cash movements
|
(41)
|
|
(52)
|
|
|
|
|
|
|
Decrease/(increase)
in net debt from continuing operations
|
(753)
|
|
174
|
|
Decrease/(increase)
in net debt from discontinued operations
|
-
|
|
313
|
|
|
|
|
|
|
Total
Net debt at end of the period
|
(17,950)
|
|
(19,351)
|
|
|
|
|
|
|
Net debt analysis
|
|
|
31 March
2023
£m
|
|
31
December
2022
£m
|
|
|
|
|
|
|
Liquid
investments
|
65
|
|
67
|
|
Cash
and cash equivalents
|
2,890
|
|
3,723
|
|
Short-term
borrowings
|
(4,261)
|
|
(3,952)
|
|
Long-term
borrowings
|
(16,644)
|
|
(17,035)
|
|
|
|
|
|
|
Total
Net debt at the end of the period
|
(17,950)
|
|
(17,197)
|
|
|
|
|
|
|
Free cash flow reconciliation from
continuing operations
|
|
|
Q1 2023
£m
|
|
Q1
2022
£m
|
|
|
|
|
|
|
Net
cash inflow/(outflow) from continuing operating
activities
|
53
|
|
2,206
|
|
Purchase of
property, plant and equipment
|
(233)
|
|
(193)
|
|
Proceeds from sale
of property, plant and equipment
|
7
|
|
6
|
|
Purchase of
intangible assets
|
(296)
|
|
(377)
|
|
Proceeds from
disposals of intangible assets
|
4
|
|
5
|
|
Net
finance costs
|
(91)
|
|
(74)
|
|
Dividends
from joint ventures and associates
|
1
|
|
-
|
|
Contingent
consideration paid (reported in investing activities)
|
(1)
|
|
(26)
|
|
Distributions to
non-controlling interests
|
(140)
|
|
(78)
|
|
Contributions from
non-controlling interests
|
7
|
|
8
|
|
|
|
|
|
|
Free
cash inflow from continuing operations
|
(689)
|
|
1,477
|
|
|
|
|
|
|
R&D
commentary
|
|
Pipeline overview
|
|
Medicines
and vaccines in phase III development (including major lifecycle
innovation or under regulatory review)
|
17
|
Infectious Diseases (7)
|
|
|
●
|
RSV
older adult vaccine candidate
|
||
|
●
|
SKYCovione
(SK) COVID-19
|
||
|
●
|
gepotidacin
(bacterial topoisomerase inhibitor) uncomplicated urinary tract
infection and urogenital gonorrhoea
|
||
|
●
|
bepirovirsen
(HBV ASO) hepatitis B virus
|
||
|
●
|
Bexsero infants vaccine (US)
|
||
|
●
|
MenABCWY
(gen 1) vaccine candidate
|
||
|
●
|
tebipenem
pivoxil (antibacterial carbapenem) complicated urinary tract
infection
|
||
|
|
|
||
|
Immunology/Respiratory (3)
|
|||
|
●
|
Nucala chronic obstructive pulmonary disease
|
||
|
●
|
depemokimab
(long acting anti-IL5) severe eosinophilic asthma, eosinophilic
granulomatosis with polyangiitis, chronic rhinosinusitis with nasal
polyps, hyper-eosinophilic syndrome
|
||
|
●
|
latozinemab
(AL001, anti-sortilin) frontotemporal dementia
|
||
|
|
|
||
|
Oncology (5)
|
|||
|
●
|
momelotinib
(JAK1, JAK2 and ACVR1 inhibitor) myelofibrosis with
anaemia
|
||
|
●
|
Blenrep (anti-BCMA ADC) multiple myeloma
|
||
|
●
|
Jemperli (anti-PD-1) 1L endometrial cancer
|
||
|
●
|
Zejula (PARP inhibitor) 1L ovarian, and lung
cancer
|
||
|
●
|
cobolimab
(anti-TIM-3) non-small cell lung cancer
|
||
|
|
|
||
|
Opportunity driven (2)
|
|||
|
●
|
Jesduvroq (HIF-PHI) anaemia of chronic kidney
disease
|
||
|
●
|
linerixibat
(IBATi) cholestatic pruritus in primary biliary
cholangitis
|
||
|
Total
vaccines and medicines in all phases of clinical
development
|
68
|
|
|
|
Total
projects in clinical development (inclusive of all phases and
indications)
|
86
|
|
|
|
Our key growth assets by therapy
area
|
|
The following outlines several key vaccines and medicines by
therapy area that will help drive growth for GSK to meet its
outlooks and ambition for 2021-2026 and beyond.
|
|
Infectious Diseases
|
|
bepirovirsen (HBV ASO)
|
|
Bepirovirsen is a potential new treatment option for people with
chronic hepatitis B being evaluated a monotherapy or combination
therapy with both existing and novel treatments. Two randomised,
double-blind, placebo-controlled phase III trials (B-Well 1 and
B-Well 2) evaluating the safety and efficacy of bepirovirsen
started in Q1 2023 and are actively recruiting
patients.
|
|
Key
trials for bepirovirsen:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
B-Well 1 bepirovirsen in nucleos(t)ide treated patients (chronic
hepatitis B)
NCT05630807
|
III
|
A multi-centre, randomised, double-blind, placebo-controlled trial
to confirm the efficacy and safety of treatment with bepirovirsen
in participants with chronic hepatitis B virus
|
Trial Start:
Q1 2023
|
Recruiting
|
|
B-Well 2 bepirovirsen in nucleos(t)ide treated patients (chronic
hepatitis B)
NCT05630820
|
III
|
A multi-centre, randomised, double-blind, placebo-controlled trial
to confirm the efficacy and safety of treatment with bepirovirsen
in participants with chronic hepatitis B virus
|
Trial Start:
Q1 2023
|
Recruiting
|
|
B-Clear bepirovirsen monotherapy (chronic hepatitis B)
NCT04449029
|
IIb
|
A multi-centre, randomised, partial-blind parallel cohort trial to
assess the efficacy and safety of treatment with bepirovirsen in
participants with chronic hepatitis B virus
|
Trial start:
Q3 2020
|
Complete;
full data presented
|
|
B-Together bepirovirsen sequential combination therapy with
Peg-interferon (chronic hepatitis B)
NCT04676724
|
IIb
|
A multi-centre, randomised, open label trial to assess the efficacy
and safety of sequential treatment with bepirovirsen followed by
Pegylated Interferon Alpha 2a in participants with chronic
hepatitis B virus
|
Trial start:
Q1 2021
|
Active, not recruiting
|
|
bepirovirsen sequential combination therapy with targeted
immunotherapy
(chronic hepatitis B)
NCT05276297
|
II
|
A trial on the safety, efficacy and immune response following
sequential treatment with an anti-sense oligonucleotide against
chronic hepatitis B (CHB) and chronic hepatitis B targeted
immunotherapy (CHB-TI) in CHB patients receiving nucleos(t)ide
analogue (NA) therapy
|
Trial start:
Q2 2022
|
Recruiting
|
|
gepotidacin (bacterial topoisomerase inhibitor)
|
|
In
April 2023, GSK presented positive results from the pivotal EAGLE-2
and EAGLE-3 phase III trials on 15 April 2023 for gepotidacin as a
potential treatment for uncomplicated urinary tract infections
(uUTI) in an oral presentation at the European Congress of Clinical
Microbiology and Infectious Diseases in Copenhagen, Denmark. In the
EAGLE-2 and EAGLE-3 phase III trials, gepotidacin demonstrated
non-inferiority to nitrofurantoin, an existing first-line treatment
for uUTI, in patients with a confirmed uUTI and a uropathogen
susceptible to nitrofurantoin. Additionally, in the EAGLE-3 phase
III trial, gepotidacin demonstrated statistically significant
superiority versus nitrofurantoin. These results are based on a
primary efficacy endpoint of therapeutic success, an endpoint
comprised of combined clinical resolution and microbiological
eradication of bacteria at the Test-of-Cure (ToC) visit 10-13 days
after initiation of treatment. In the EAGLE-2 phase III trial,
gepotidacin demonstrated therapeutic success in 50.6% of patients
compared to 47% for nitrofurantoin. In the EAGLE-3 phase III trial,
gepotidacin demonstrated therapeutic success in 58.5% of patients
compared to 43.6% for nitrofurantoin. The safety and tolerability
profile of gepotidacin in the EAGLE-2 and EAGLE-3 phase III trials
was consistent with previous trials.
The
presentation follows the decision to stop the EAGLE-2 and EAGLE-3
pivotal trials early for efficacy following a recommendation made
by the Independent Data Monitoring Committee in November 2022. The
full results will be submitted for publication in a peer-reviewed
scientific journal later this year.
|
|
Key
phase III trials for gepotidacin:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
EAGLE-1 (uncomplicated urogenital gonorrhoea)
NCT04010539
|
III
|
A randomised, multi-centre, open-label trial in adolescent and
adult participants comparing the efficacy and safety of gepotidacin
to ceftriaxone plus azithromycin in the treatment of uncomplicated
urogenital gonorrhoea caused by Neisseria
gonorrhoeae
|
Trial start:
Q4 2019
|
Recruiting
|
|
EAGLE-2 (females with uUTI / acute cystitis)
NCT04020341
|
III
|
A randomised, multi-centre, parallel-group, double-blind,
double-dummy trial in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial start:
Q4 2019
|
Complete; primary endpoint met
|
|
EAGLE-3 (females with uUTI / acute cystitis)
NCT04187144
|
III
|
A randomised, multi-centre, parallel-group, double-blind,
double-dummy trial in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial start:
Q2 2020
|
Complete; primary endpoint met
|
|
MenABCWY vaccine candidate
|
|
GSK’s
MenABCWY combination vaccine candidate met all primary endpoints of
the pivotal phase III clinical trial and was well tolerated with a
safety profile consistent with Bexsero and Menveo. The primary endpoint data
demonstrated statistical non-inferiority compared to Bexsero and Menveo in individuals 10-25 years old,
eliciting a clinically meaningful immune response. If approved,
this five-in-one vaccine candidate could provide the broadest
meningococcal serogroup coverage and could lead to a simplified
immunisation schedule. Detailed results from this phase III trial
will be presented in a peer-reviewed publication and at upcoming
scientific meetings. Based on these results, GSK intends to submit
a Biologics License Application to the US Food and Drug
Administration (FDA) to approve of its MenABCWY combination vaccine
candidate.
|
|
Key
trials for MenABCWY vaccine candidate:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
MenABCWY – 019
NCT04707391
|
IIIb
|
A randomised, controlled, observer-blind trial to evaluate safety
and immunogenicity of GSK’s meningococcal ABCWY vaccine when
administered in healthy adolescents and adults, previously primed
with meningococcal ACWY vaccine
|
Trial start:
Q1 2021
|
Active, not recruiting
|
|
MenABCWY – V72 72
NCT04502693
|
III
|
A randomised, controlled, observer-blind trial to demonstrate
effectiveness, immunogenicity, and safety of GSK's meningococcal
Group B and combined ABCWY vaccines when administered to healthy
adolescents and young adults
|
Trial
start:
Q3
2020
|
Complete; primary endpoints met
|
|
RSV vaccine candidates
|
|
In March 2023, the US FDA Vaccines and Related Biological Products
Advisory Committee (VRBPAC) voted that the available data supported
the safety and effectiveness of GSK’s respiratory syncytial
virus (RSV) older adult vaccine candidate for the prevention of
lower respiratory tract disease caused by RSV in adults aged 60
years and older. The Committee voted unanimously 12-0 on
effectiveness and 10-2 on safety. The US FDA has assigned a
Prescription Drug User Fee Act action date of 3 May 2023.
Regulatory reviews are ongoing elsewhere, including in the EU and
Japan.
The VRBPAC vote followed the publication of positive phase III
trial results for the vaccine candidate in The New England Journal of
Medicine.
|
|
Key
phase III trials for RSV older adult vaccine
candidates:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RSV OA=ADJ-004
(Adults ≥ 60 years old)
NCT04732871
|
III
|
A randomised, open-label, multi-country trial to evaluate the
immunogenicity, safety, reactogenicity and persistence of a single
dose of the RSVPreF3 OA investigational vaccine and different
revaccination schedules in adults aged 60 years and
above
|
Trial start:
Q1 2021
|
Active, not recruiting; primary endpoint met
|
|
RSV OA=ADJ-006
(ARESVI-006; Adults ≥ 60 years old)
NCT04886596
|
III
|
A randomised, placebo-controlled, observer-blind, multi-country
trial to demonstrate the efficacy of a single dose of GSK’s
RSVPreF3 OA investigational vaccine in adults aged 60 years and
above
|
Trial start:
Q2 2021
|
Active, not recruiting; primary endpoint met
|
|
RSV OA=ADJ-007
(Adults ≥ 60 years old)
NCT04841577
|
III
|
An open-label, randomised, controlled, multi-country trial to
evaluate the immune response, safety and reactogenicity of RSVPreF3
OA investigational vaccine when co-administered with FLU-QIV
vaccine in adults aged 60 years and above
|
Trial start:
Q2 2021
|
Complete; primary endpoint met
|
|
RSV OA=ADJ-008
(Adults ≥ 65 years old)
NCT05559476
|
III
|
A phase III, open-label, randomised, controlled, multi country
trial to evaluate the immune response, safety and reactogenicity of
RSVPreF3 OA investigational vaccine when co-administered with FLU
HD vaccine in adults aged 65 years and above
|
Trial start:
Q4 2022
|
Active, not recruiting
|
|
RSV OA=ADJ-009
(Adults ≥ 60 years old)
NCT05059301
|
III
|
A randomised, double-blind, multi-country trial to evaluate
consistency, safety, and reactogenicity of 3 lots of RSVPreF3 OA
investigational vaccine administrated as a single dose in adults
aged 60 years and above
|
Trial start:
Q4 2021
|
Complete; primary endpoint met
|
|
RSV OA=ADJ-017
(Adults ≥ 65 years old)
NCT05568797
|
III
|
A phase III, open-label, randomised, controlled, multi-country
trial to evaluate the immune response, safety and reactogenicity of
an RSVPreF3 OA investigational vaccine when co-administered with
FLU aQIV (inactivated influenza vaccine – adjuvanted) in
adults aged 65 years and above
|
Trial start:
Q4 2022
|
Active, not recruiting
|
|
RSV OA=ADJ-018
(Adults 50-59 years)
NCT05590403
|
III
|
A phase III, observer-blind, randomised, placebo-controlled trial
to evaluate the non-inferiority of the immune response and safety
of the RSVPreF3 OA investigational vaccine in adults 50 59 years of
age, including adults at increased risk of respiratory syncytial
virus lower respiratory tract disease, compared to older adults
≥60 years of age.
|
Trial start:
Q4 2022
|
Active, not recruiting
|
|
HIV
|
|
cabotegravir
|
|
In February 2023, ViiV Healthcare announced positive 12-month
findings from the SOLAR phase IIIb trial, presented at the 30th
Conference on Retroviruses and Opportunistic Infections, in
Seattle, Washington. SOLAR is the first head-to-head, phase IIIb
trial of the first and only complete long-acting injectable
regimen Cabenuva (cabotegravir, rilpivirine) compared against
complete daily oral regimen bictegravir/emtricitabine/tenofovir
alafenamide.
The trial showed that Cabenuva dosed every two months achieved the primary
endpoint of non-inferior virologic efficacy versus daily oral
bictegravir/emtricitabine/tenofovir alafenamide. At the same time,
90% of participants who switched to Cabenuva from bictegravir/emtricitabine/tenofovir
alafenamide, and who completed a survey (n=425), preferred the
long-acting regimen. Switching to Cabenuva from bictegravir/emtricitabine/tenofovir
alafenamide during the SOLAR trial was efficacious, well-tolerated,
and improved treatment satisfaction from baseline based on adjusted
HIV Treatment Satisfaction Questionnaire status version
scores.
Additionally, together with the Medicines Patent Pool (MPP), ViiV
announced that MPP has signed sublicence agreements with Aurobindo
Pharma, Cipla Inc. and Viatris Inc – through its subsidiary
Mylan – to manufacture generic versions of cabotegravir
long-acting (LA) for HIV pre-exposure prophylaxis (PrEP). This is
enabled by signing a voluntary licensing agreement for patents
relating to cabotegravir LA for PrEP with MPP in July 2022. Through
the MPP-ViiV Healthcare agreement, the selected generic
manufacturers will be able to develop, manufacture, and supply
generic versions of cabotegravir LA for PrEP, in 90 countries,
subject to required regulatory approvals being
obtained.
|
|
Key
phase III trials for cabotegravir:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
HPTN 083
(HIV uninfected cisgender men and transgender women who have sex
with men)
NCT02720094
|
IIb/III
|
A double-blind safety and efficacy trial of injectable cabotegravir
compared to daily oral tenofovir disoproxil fumarate/emtricitabine
(TDF/FTC), for Pre-Exposure Prophylaxis in HIV-uninfected cisgender
men and transgender women who have sex with men
|
Trial start:
Q4 2016
|
Active; not recruiting; primary endpoint met
(superiority)
|
|
HPTN 084
(HIV uninfected women who are at high risk of acquiring
HIV)
NCT03164564
|
III
|
A double-blind safety and efficacy trial of long-acting injectable
cabotegravir compared to daily oral TDF/FTC for Pre-Exposure
Prophylaxis in HIV-Uninfected women
|
Trial start:
Q4 2017
|
Active; not recruiting; primary endpoint met
(superiority)
|
|
ATLAS
NCT02951052
|
III
|
A randomised, multi-centre, parallel-group, non-inferiority,
open-label trial evaluating the efficacy, safety, and tolerability
of switching to long-acting cabotegravir plus long-acting
rilpivirine from current INI- NNRTI-, or PI-based antiretroviral
regimen in HIV-1-infected adults who are virologically
suppressed
|
Trial start:
Q4 2016
|
Active; not recruiting; primary endpoint met
(non-inferiority)
|
|
ATLAS-2M
NCT03299049
|
IIIb
|
A randomised, multi-centre, parallel-group, non-inferiority,
open-label trial evaluating the efficacy, safety, and tolerability
of long-acting cabotegravir plus long-acting rilpivirine
administered every 8 weeks or every 4 weeks in HIV-1-infected
adults who are virologically suppressed
|
Trial start:
Q4 2017
|
Active; not recruiting; primary endpoint met
(non-inferiority)
|
|
FLAIR
NCT02938520
|
III
|
A randomised, multi-centre, parallel-group, open-label trial
evaluating the efficacy, safety, and tolerability of long-acting
intramuscular cabotegravir and rilpivirine for maintenance of
virologic suppression following switch from an integrase inhibitor
single tablet regimen in HIV-1 infected antiretroviral therapy
naïve adult participants
|
Trial
start:
Q4
2016
|
Active; not recruiting; primary endpoint met
(non-inferiority)
|
|
Immunology/Respiratory
|
|
depemokimab (ultra-long-acting anti-IL5)
|
|
The phase III programme for our ultra-long-acting IL5 inhibitor,
depemokimab continues to make progress across a range of
eosinophil-driven diseases. Phase III trials of depemokimab were
initiated in the second half of 2022 in indications for chronic
rhinosinusitis with nasal polyps (CRSwNP), eosinophilic
granulomatosis with polyangiitis (EGPA) and hypereosinophilic
syndrome (HES). Trials of depemokimab in severe eosinophilic asthma
which started in 2021 continued throughout 2022 with the open label
extension of these trials starting recruitment in Q1 of 2022.
Depemokimab is a unique and distinct monoclonal antibody developed
specifically for its affinity for IL-5 and long duration of
inhibition.
|
|
Key
phase III trials for depemokimab:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
SWIFT-1 (severe eosinophilic asthma; SEA)
NCT04719832
|
III
|
A 52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre trial of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial start:
Q1 2021
|
Active, not recruiting
|
|
SWIFT-2 (SEA)
NCT04718103
|
III
|
A 52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre trial of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial start:
Q1 2021
|
Recruiting
|
|
AGILE (SEA)
NCT05243680
|
III (extension)
|
A 52-week, open label extension phase of SWIFT-1 and SWIFT-2 to
assess the long-term safety and efficacy of depemokimab adjunctive
therapy in adult and adolescent participants with severe
uncontrolled asthma with an eosinophilic phenotype
|
Trial start:
Q1 2022
|
Recruiting
|
|
NIMBLE (SEA)
NCT04718389
|
III
|
A 52-week, randomised, double-blind, double-dummy, parallel group,
multi-centre, non-inferiority trial assessing exacerbation rate,
additional measures of asthma control and safety in adult and
adolescent severe asthmatic participants with an eosinophilic
phenotype treated with depemokimab compared with mepolizumab or
benralizumab
|
Trial start:
Q1 2021
|
Recruiting
|
|
ANCHOR-1 (CRSwNP)
NCT05274750
|
III
|
Efficacy and safety of depemokimab in participants with
CRSwNP
|
Trial start:
Q2 2022
|
Recruiting
|
|
ANCHOR-2 (CRSwNP)
NCT05281523
|
III
|
Efficacy and safety of depemokimab in participants with
CRSwNP
|
Trial start:
Q2 2022
|
Recruiting
|
|
OCEAN (EGPA)
NCT05263934
|
III
|
Efficacy and safety of depemokimab compared with mepolizumab in
adults with relapsing or refractory EGPA
|
Trial start:
Q3 2022
|
Recruiting
|
|
DESTINY (HES)
NCT05334368
|
III
|
A 52-week, randomised, placebo-controlled, double-blind, parallel
group, multicentre trial of depemokimab in adults with uncontrolled
HES receiving standard of care (SoC) therapy
|
Trial start:
Q4 2022
|
Recruiting
|
|
Oncology
|
|
Blenrep
(belantamab mafodotin)
|
|
Trials
within the DREAMM (DRiving Excellence in Approaches to Multiple
Myeloma) clinical trial programme are ongoing, evaluating
belantamab mafodotin in earlier lines of therapy and in
combination. We anticipate data from DREAMM-7 and DREAMM-8 in the
second-line setting in the second half of 2023.
|
|
Key
phase III trials for Blenrep:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
DREAMM-7 (2L+ MM pts)
NCT04246047
|
III
|
A multi-centre, open-label, randomised trial to evaluate the
efficacy and safety of the combination of belantamab mafodotin,
bortezomib, and dexamethasone (B-Vd) compared with the combination
of daratumumab, bortezomib and dexamethasone (D-Vd) in participants
with relapsed/refractory multiple myeloma
|
Trial start:
Q2 2020
|
Active, not recruiting
|
|
DREAMM-8 (2L+ MM pts)
NCT04484623
|
III
|
A multi-centre, open-label, randomised trial to evaluate the
efficacy and safety of belantamab mafodotin in combination with
pomalidomide and dexamethasone (B-Pd) versus pomalidomide plus
bortezomib and dexamethasone (P-Vd) in participants with
relapsed/refractory multiple myeloma
|
Trial start:
Q4 2020
|
Enrolment complete
|
|
Jemperli
(dostarlimab)
|
|
In
February 2023, the US FDA Oncologic Drugs Advisory Committee voted
in support of trials designed to evaluate Jemperli as a potential treatment for
mismatch repair-deficient/microsatellite instability-high
(dMMR/MSI-H) locally advanced rectal cancer. Following the
committee’s positive vote, in March 2023, GSK initiated a
global, open-label, phase II clinical trial to investigate the
efficacy and safety of dostarlimab as monotherapy – as a
replacement for chemotherapy, radiation and/or surgery – for
treatment-naïve patients with dMMR/MSI-H locally advanced
rectal cancer. The first patient was dosed in April 2023. GSK
intends to use data from this trial, alongside data from Memorial
Sloan Kettering Cancer Center’s ongoing trial of 30 patients,
to support a supplemental Biologics License Application (sBLA) for
accelerated regulatory approval in this indication. Earlier in Q1
2023, the US FDA granted dostarlimab Fast Track designation for the
treatment of dMMR/MSI-H locally advanced rectal
cancer.
In
February 2023, the US FDA granted full approval for Jemperli for the treatment of adult
patients with dMMR recurrent or advanced endometrial cancer, as
determined by a US FDA-approved test, that has progressed on or
following a prior platinum-containing regimen in any setting and
are not candidates for curative surgery or radiation. This approval
was based on additional data collected from the A1 expansion cohort
of the ongoing GARNET phase I trial, a multicentre, open-label,
single-arm trial of Jemperli monotherapy in patients with
advanced or recurrent solid tumours. Long-term outcomes from GARNET
demonstrated an overall response rate of 45.4%.
In
March 2023, GSK announced interim results from Part 1 of the
RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating
dostarlimab plus standard-of-care chemotherapy
(carboplatin-paclitaxel) followed by dostarlimab compared to
chemotherapy plus placebo followed by placebo in adult patients
with primary advanced or recurrent endometrial cancer. The results
demonstrated the potential of dostarlimab plus chemotherapy to
redefine the treatment of primary advanced or recurrent endometrial
cancer versus chemotherapy alone. A 72% and 36% reduction in the
risk of disease progression or death were observed in the
dMMR/MSI-H and overall patient populations, respectively. A
clinically meaningful overall survival trend was also observed at
the interim analysis.
In
April 2023, GSK announced that the European Medicines Agency (EMA)
validated the marketing authorisation application (MAA) for
Jemperli plus chemotherapy
for the treatment of dMMR/MSI-H primary advanced or recurrent
endometrial cancer.
|
|
Key
trials for Jemperli:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RUBY
ENGOT-EN6
GOG-3031 (1L Stage III or IV endometrial cancer)
NCT03981796
|
III
|
A randomised, double-blind, multi-centre trial of dostarlimab plus
carboplatin-paclitaxel with and without niraparib maintenance
versus placebo plus carboplatin-paclitaxel in patients with
recurrent or primary advanced endometrial cancer
|
Trial start:
Q3 2019
|
Active, not recruiting; primary endpoint met in RUBY Part
1
|
|
PERLA (1L metastatic non-small cell lung cancer)
NCT04581824
|
II
|
A randomised, double-blind trial to evaluate the efficacy of
dostarlimab plus chemotherapy versus pembrolizumab plus
chemotherapy in metastatic non-squamous non-small cell lung
cancer
|
Trial start:
Q4 2020
|
Active, not recruiting; primary endpoint met
|
|
GARNET (advanced solid tumours)
NCT02715284
|
I/II
|
A multi-center, open-label, first-in-human trial evaluating
dostarlimab in participants with advanced solid tumors who have
limited available treatment options
|
Trial start:
Q1 2016
|
Recruiting
|
|
AZUR-1 (locally advanced rectal cancer)
NCT05723562
|
II
|
A single-arm, open-label trial with dostarlimab monotherapy in
participants with untreated stage II/III dMMR/MSI-H locally
advanced rectal cancer
|
Trial start:
Q1 2023
|
Recruiting
|
|
momelotinib (JAK1/2 and ACVR1/ALK2 inhibitor)
|
|
A
European Union MAA for momelotinib, a potential new oral treatment
for myelofibrosis, is currently under review with the EMA. A
Committee for Medicinal Products for Human Use (CHMP) regulatory
action is anticipated by year-end 2023. A New Drug Application
(NDA) for momelotinib is also currently under regulatory review by
the US FDA with a Prescription Drug User Fee Act action date of 16
June 2023.
|
|
Key
phase III trial for momelotinib:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
MOMENTUM (myelofibrosis)
NCT04173494
|
III
|
A randomised, double-blind, active control phase III trial intended
to confirm the differentiated clinical benefits of the
investigational drug momelotinib (MMB) versus danazol (DAN) in
symptomatic and anaemic subjects who have previously received an
approved Janus kinase inhibitor (JAKi) therapy for myelofibrosis
(MF)
|
Trial start:
Q1 2020
|
Active, not recruiting; primary endpoint met
|
|
Zejula
(niraparib)
|
|
Zejula is approved in more than
40 countries as a maintenance treatment for certain types of
ovarian, fallopian tube and primary peritoneal cancer. The ongoing
development programme includes several combination trials,
including the FIRST phase III trial assessing niraparib in
combination with dostarlimab as a potential treatment for
first-line ovarian cancer maintenance and the phase III ZEAL trial
assessing niraparib in combination with standard of care for the
maintenance treatment of first-line advanced non-small cell lung
cancer.
In
April 2023, GSK took the decision to
permanently discontinue enrolment in the ZEST phase III 800-patient
trial, initiated in 2021. This decision was due to eligibility
challenges impacting the ability to fully enrol patients with
early-stage breast cancer. During the conduct of the trial, GSK
learned that the prevalence of a radiologically detectable
metastatic disease among patients who are ctDNA positive is much
higher than expected. This enabled patients to be referred for
treatment of metastatic cancer ahead of clinical symptoms.
Consequently, because these patients were ineligible for the ZEST
phase III trial, it has made enrolment in the trial much more
challenging than previously thought.
|
|
Key
phase III trials for Zejula:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
ZEAL-1L (maintenance for 1L advanced NSCLC)
NCT04475939
|
III
|
A randomised, double-blind, placebo-controlled, multi-centre trial
comparing niraparib plus pembrolizumab versus placebo plus
pembrolizumab as maintenance therapy in participants whose disease
has remained stable or responded to first-line platinum-based
chemotherapy with pembrolizumab for Stage IIIB/IIIC or IV non-small
cell lung cancer
|
Trial start:
Q4 2020
|
Active, not recruiting
|
|
FIRST (1L ovarian cancer maintenance)
NCT03602859
|
III
|
A randomised, double-blind, comparison of platinum-based therapy
with dostarlimab (TSR-042) and niraparib versus standard of care
platinum-based therapy as first-line treatment of stage III or IV
non-mucinous epithelial ovarian cancer
|
Trial start:
Q4 2018
|
Active, not recruiting
|
|
Opportunity driven
|
|
Jesduvroq
(daprodustat)
|
|
In
February 2023, the US FDA approved Jesduvroq (daprodustat) for the
treatment of anaemia due to chronic kidney disease (CKD) in adults
who have been receiving dialysis for at least four months.
Jesduvroq is the first
innovative medicine for anaemia treatment in over 30 years and the
only hypoxia-inducible factor prolyl hydroxylase inhibitor approved
in the US, providing a new oral, convenient option for patients in
the US with anaemia of CKD on dialysis and for healthcare
providers. Jesduvroq is
currently under regulatory review with the EMA, with a regulatory
decision anticipated in the first half of 2023.
When
left untreated or undertreated, anaemia of CKD is associated with
poor clinical outcomes and leads to a substantial burden on
patients and healthcare systems. There remains an unmet need for
convenient treatment options with efficacy and safety comparable to
current treatments.
|
|
Key
phase III trials for daprodustat:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
ASCEND-D (Dialysis subjects with anaemia of CKD)
NCT02879305
|
III
|
A randomised, open-label (sponsor-blind), active-controlled,
parallel-group, multi-centre, event driven trial in dialysis
subjects with anaemia associated with chronic kidney disease to
evaluate the safety and efficacy of daprodustat compared to
recombinant human erythropoietin, following a switch from
erythropoietin-stimulating agents
|
Reported
|
Complete; primary endpoint met
|
|
ASCEND-ID (Incident Dialysis subjects with anaemia of
CKD)
NCT03029208
|
III
|
A 52-week open-label (sponsor-blind), randomised,
active-controlled, parallel-group, multi-centre trial to evaluate
the efficacy and safety of daprodustat compared to recombinant
human erythropoietin in subjects with anaemia of chronic kidney
disease who are initiating dialysis
|
Reported
|
Complete; primary endpoint met
|
|
ASCEND-TD (Dialysis subjects with anaemia of CKD)
NCT03400033
|
III
|
A randomised, double-blind, active-controlled, parallel-group,
multi-centre trial in haemodialysis participants with anaemia of
chronic kidney disease to evaluate the efficacy, safety, and
pharmacokinetics of three-times weekly dosing of daprodustat
compared to recombinant human erythropoietin, following a switch
from recombinant human erythropoietin or its analogues
|
Reported
|
Complete; primary endpoint met
|
|
ASCEND-ND (Non-dialysis subjects with anaemia of CKD)
NCT02876835
|
III
|
A randomised, open-label (sponsor-blind), active-controlled,
parallel-group, multi-centre, event driven trial in non-dialysis
subjects with anaemia of chronic kidney disease to evaluate the
safety and efficacy of daprodustat compared to darbepoetin
alfa
|
Reported
|
Complete; primary endpoint met
|
|
ASCEND-NHQ (Non-dialysis subjects with anaemia of CKD)
NCT03409107
|
III
|
A 28-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre, trial in recombinant human
erythropoietin (rhEPO) naïve non-dialysis participants with
anaemia of chronic kidney disease to evaluate the efficacy, safety,
and effects on quality of life of daprodustat compared to
placebo
|
Reported
|
Complete; primary endpoint met
|
|
Reporting
definitions
|
|
Total, Continuing and Adjusted results
Total
reported results represent the Group’s overall performance
including discontinued operations. Continuing results represents
performance excluding discontinued operations.
GSK
also uses a number of adjusted, non-IFRS, measures to report the
performance of its business. Adjusted results and other non-IFRS
measures may be considered in addition to, but not as a substitute
for or superior to, information presented in accordance with IFRS.
Adjusted results are defined on page 16 and other non-IFRS measures
are defined below and are based on continuing
operations.
Free cash flow from continuing operations
Free
cash flow is defined as the net cash inflow/outflow from continuing
operating activities less capital expenditure on property, plant
and equipment and intangible assets, contingent consideration
payments, net finance costs, and dividends paid to non-controlling
interests, contributions from non-controlling interests plus
proceeds from the sale of property, plant and equipment and
intangible assets, and dividends received from joint ventures and
associates (all attributable to continuing operations). It is used
by management for planning and reporting purposes and in
discussions with and presentations to investment analysts and
rating agencies. Free cash flow growth is calculated on a reported
basis. A reconciliation of net cash inflow from continuing
operations to free cash flow from continuing operations is set out
on page 34.
Free cash flow conversion
Free
cash flow conversion is free cash flow from continuing operations
as a percentage of profit attributable to shareholders from
continuing operations.
Working capital
Working
capital represents inventory and trade receivables less trade
payables.
CER and AER growth
In
order to illustrate underlying performance, it is the Group’s
practice to discuss its results in terms of constant exchange rate
(CER) growth. This represents growth calculated as if the exchange
rates used to determine the results of overseas companies in
Sterling had remained unchanged from those used in the comparative
period. CER% represents growth at constant exchange rates. £%
or AER% represents growth at actual exchange rates.
Total Net debt
Net debt is defined as total borrowings less cash, cash
equivalents, liquid investments, and short-term loans to third
parties that are subject to an insignificant risk of change in
value.
Share Consolidation
Shareholders
received 4 new Ordinary shares with a nominal value of 31¼
pence each for every 5 existing Ordinary shares which had a nominal
value of 25 pence each. Earnings per share, diluted earnings per
share, adjusted earnings per share and dividends per share were
retrospectively adjusted to reflect the Share Consolidation in all
the periods presented.
Earnings per share
Earnings
per share has been retrospectively adjusted for the Share
Consolidation on 18 July 2022, applying a ratio of 4 new Ordinary
shares for every 5 existing Ordinary shares.
Total Earnings per share
Unless
otherwise stated, Total earnings per share refers to Total basic
earnings per share.
Total Operating Margin
Total Operating margin is operating profit divided by
turnover.
COVID-19 solutions
COVID-19
solutions include the sales of pandemic adjuvant and other COVID-19
solutions including vaccine manufacturing and Xevudy and the associated costs but
does not include reinvestment in R&D. This categorisation is
used by management and we believe is helpful to investors through
providing clarity on the results of the Group by showing the
contribution to growth from COVID-19 solutions.
Turnover excluding COVID-19 solutions
Turnover
excluding COVID-19 solutions excludes the impact of sales of
pandemic adjuvant within Vaccines and Xevudy within Specialty Medicines
related to the COVID-19 pandemic. Management believes that the
exclusion of the impact of these COVID-19 solutions sales aids
comparability in the reporting periods and understanding of
GSK’s growth including by region versus prior periods and
also 2023 Guidance which excludes any contributions from COVID-19
solutions.
General Medicines
General
Medicines are usually prescribed in the primary care or community
settings by general healthcare practitioners. For GSK, this
includes medicines in inhaled respiratory, dermatology, antibiotics
and other diseases.
Specialty Medicines
Specialty
Medicines are typically prescription medicines used to treat
complex or rare chronic conditions. For GSK, this comprises
medicines in infectious diseases, HIV, oncology,
immunology/respiratory and Other.
Percentage points
Percentage points of growth which is abbreviated to
ppts.
|
|
Brand
names and partner acknowledgements
Brand names appearing in italics throughout this
document are trademarks of GSK or associated companies or used
under licence by the Group.
|
|
Guidance, assumptions and cautionary
statements
|
|
2023 guidance
GSK
expects 2023 turnover to increase between 6 to 8 per cent, Adjusted
operating profit to increase between 10 to 12 per cent and Adjusted
earnings per share to increase between 12 to 15 per cent. This
guidance is provided at CER and excludes any contributions from
COVID-19 solutions.
Assumptions related to 2023 guidance
In
outlining the guidance for 2023, the Group has made certain
assumptions about the healthcare sector, the different markets in
which the Group operates and the delivery of revenues and financial
benefits from its current portfolio, pipeline and restructuring
programmes. Taking Q1 2023 performance and the latest expectations
for Q2 2023 into account, GSK now expects first half and second
half turnover growth to be broadly similar and for General
Medicines to be broadly flat to slightly down this year. GSK
expects Adjusted operating profit growth to be lower in the first
half of 2023 and higher in the second half, relative to full-year
expectations. Despite the recovery of healthcare systems, uncertain
economic conditions prevail across many markets in which GSK
operates and we continue to expect to see variability in
performance between quarters.
We
expect sales of Vaccines to increase mid-teens per cent, Specialty
Medicines to increase mid to high single-digit per cent, and sales
of General Medicines to be broadly flat to slightly
down.
These
planning assumptions as well as operating profit guidance and
dividend expectations assume no material interruptions to supply of
the Group’s products, no material mergers, acquisitions or
disposals, no material litigation or investigation costs for the
Company (save for those that are already recognised or for which
provisions have been made) and no change in the Group’s
shareholdings in ViiV Healthcare. The assumptions also assume no
material changes in the healthcare environment or unexpected
significant changes in pricing as a result of government or
competitor action. The 2023 guidance factors in all divestments and
product exits announced to date.
The
Group’s guidance assumes successful delivery of the
Group’s integration and restructuring plans. Material costs for investment in new product
launches and R&D have been factored into the expectations
given. Given the potential development options in the Group’s
pipeline, the outlook may be affected by additional data-driven
R&D investment decisions. The guidance is given on a constant
currency basis.
Assumptions and cautionary statement regarding forward-looking
statements
The
Group’s management believes that the assumptions outlined
above are reasonable, and that the guidance, outlooks, ambitions
and expectations described in this report are achievable based on
those assumptions. However, given the forward-looking nature of
these guidance, outlooks, ambitions and expectations, they are
subject to greater uncertainty, including potential material
impacts if the above assumptions are not realised, and other
material impacts related to foreign exchange fluctuations,
macro-economic activity, the impact of outbreaks, epidemics or
pandemics, such as the COVID-19 pandemic and ongoing challenges and
uncertainties posed by the COVID-19 pandemic for businesses and
governments around the world, changes in legislation, regulation,
government actions or intellectual property protection, product
development and approvals, actions by our competitors, and other
risks inherent to the industries in which we operate.
This
document contains statements that are, or may be deemed to be,
“forward-looking statements”. Forward-looking
statements give the Group’s current expectations or forecasts
of future events. An investor can identify these statements by the
fact that they do not relate strictly to historical or current
facts. They use words such as ‘anticipate’,
‘estimate’, ‘expect’, ‘intend’,
‘will’, ‘project’, ‘plan’,
‘believe’, ‘target’ and other words and
terms of similar meaning in connection with any discussion of
future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of
contingencies such as legal proceedings, dividend payments and
financial results. Other than in accordance with its legal or
regulatory obligations (including under the Market Abuse
Regulation, the UK Listing Rules and the Disclosure and
Transparency Rules of the Financial Conduct Authority), the Group
undertakes no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.
The reader should, however, consult any additional disclosures that
the Group may make in any documents which it publishes and/or files
with the SEC. All readers, wherever located, should take note of
these disclosures. Accordingly, no assurance can be given that any
particular expectation will be met and investors are cautioned not
to place undue reliance on the forward-looking
statements.
All guidance, outlooks, ambitions and expectations should be read
together with the guidance, assumptions and cautionary statements
in this Q1 2023 earnings release and the 2022 Annual
Report.
Forward-looking
statements are subject to assumptions, inherent risks and
uncertainties, many of which relate to factors that are beyond the
Group’s control or precise estimate. The Group cautions
investors that a number of important factors, including those in
this document, could cause actual results to differ materially from
those expressed or implied in any forward-looking statement. Such
factors include, but are not limited to, those discussed under Item
3.D ‘Risk Factors’ in the Group’s Annual Report
on Form 20-F for 2022 and any impacts of the COVID-19 pandemic. Any
forward looking statements made by or on behalf of the Group speak
only as of the date they are made and are based upon the knowledge
and information available to the Directors on the date of this
report.
|
|
Independent review report to GSK
plc
|
|
Conclusion
We have
been engaged by GSK plc (“the Company”) to review the
condensed financial information in the Results Announcement of the
Company for the three months ended 31 March 2023.
|
|
The
condensed financial information comprises:
|
|
|
●
|
the
income statement and statement of comprehensive income for three
month period ended 31 March 2023 on page 21 to 22;
|
|
●
|
the
balance sheet as at 31 March 2023 on page 23;
|
|
●
|
the
statement of changes in equity for the three month period then
ended on page 24;
|
|
●
|
the
cash flow statement for the three month period then ended on page
25; and
|
|
●
|
the
accounting policies and basis of preparation and the explanatory
notes to the condensed financial information on pages 26 to 34 that
have been prepared applying consistent accounting policies to those
applied by the Group in the Annual Report 2022, which was prepared
in accordance with International Financial Reporting Standards
(“IFRS”) as adopted by the United Kingdom.
|
|
|
|
|
We have
read the other information contained in the Results Announcement,
including the non-IFRS measures contained on pages 26 to 34 and
considered whether it contains any apparent misstatements or
material inconsistencies with the information in the condensed set
of financial information.
Based
on our review, nothing has come to our attention that causes us to
believe that the condensed financial information in the Results
Announcement for the three months ended 31 March 2023 is not
prepared, in all material respects in accordance with the
accounting policies set out in the accounting policies and basis of
preparation section on page 31.
Basis for Conclusion
We
conducted our review in accordance with International Standard on
Review Engagements (UK and Ireland) 2410 “Review of Interim
Financial Information Performed by the Independent Auditor of the
Entity” issued by the Financial Reporting Council for use in
the United Kingdom (ISRE(UK)2410). A review of interim financial
information consists of making inquiries, primarily of persons
responsible for financial and accounting matters, and applying
analytical and other review procedures. A review is substantially
less in scope than an audit conducted in accordance with
International Standards on Auditing (UK) and consequently does not
enable us to obtain assurance that we would become aware of all
significant matters that might be identified in an audit.
Accordingly, we do not express an audit opinion.
As
disclosed on page 31, the annual financial statements of the
Company are prepared in accordance with United Kingdom adopted
international accounting standards. The condensed set of financial
statements included in this Results Announcement have been prepared
in accordance with the accounting policies set out in the
accounting policies and basis of preparation section on page
31.
Conclusion Relating to Going Concern
Based
on our review procedures, which are less extensive than those
performed in an audit as described in the Basis for Conclusion
section of this report, nothing has come to our attention to
suggest that the directors have inappropriately adopted the going
concern basis of accounting or that the directors have identified
material uncertainties relating to going concern that are not
appropriately disclosed.
This
Conclusion is based on the review procedures performed in
accordance with ISRE (UK) 2410, however future events or conditions
may cause the entity to cease to continue as a going
concern.
Responsibilities of the directors
The
directors are responsible for preparing the Results Announcement of
the Company in accordance with the Disclosure Guidance and
Transparency Rules of the United Kingdom’s Financial Conduct
Authority.
In
preparing the Results Announcement, the directors are responsible
for assessing the Company’s ability to continue as a going
concern, disclosing as applicable, matters related to going concern
and using the going concern basis of accounting unless the
directors either intend to liquidate the Company or to cease
operations, or have no realistic alternative but to do
so.
Auditor’s Responsibilities for the review of the financial
information
In
reviewing the Results Announcement, our responsibility is to
express to the Company a conclusion on the condensed financial
information in the Results Announcement based on our review. Our
conclusion, including our Conclusions Relating to Going Concern,
are based on procedures that are less extensive than audit
procedures, as described in the Basis of Conclusion paragraph of
this report.
Use of our report
This
report is made solely to the Company in accordance with
International Standard on Review Engagements (UK and Ireland) 2410
“Review of Interim Financial Information Performed by the
Independent Auditor of the Entity” issued by the Financial
Reporting Council (ISRE (UK) 2410). Our work has been undertaken so
that we might state to the Company those matters we are required to
state to it in an independent review report and for no other
purpose. To the fullest extent permitted by law, we do not accept
or assume responsibility to anyone other than the Company, for our
review work, for this report, or for the conclusions we have
formed.
Deloitte LLP
Statutory
Auditor
London,
United Kingdom
26
April 2023
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date:
April 26, 2023
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|